{"title": "PDF", "author": "PDF", "url": "https://eprints.aihta.at/1234/62/Policy_Brief_002.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n   \n \n \n \n \n \n \n  \n \nInhalt  ................................ ................................ ................................ ................................ ........................  5 \nDeutsche Zusammenfassung  ................................ ................................ ................................ .................  7 \n1 Backgrou nd: policy question and methods\u201c  ................................ ................................ .................  23 \n1.1 Policy Question  ................................ ................................ ................................ ...............................  23 \n1.2 Methodology  ................................ ................................ ................................ ................................ ... 23 \n1.3 Selection of Products for \u201cVignettes\u201d  ................................ ................................ ............................  24 \n2 Results: Vaccines  ................................ ................................ ................................ .............................  25 \n2.1 Moderna Therapeutics \u2014US National Institute of Allergy  ................................ .........................  26 \n2.2 CanSino Biological Inc. and Beijing Institute of Biotechnology  ................................ ................  27 \n2.3 Inovio Pharmaceuticals  ................................ ................................ ................................ ..................  28 \n2.4 Novavax  ................................ ................................ ................................ ................................ ...........  28 \n2.5 University of Quee nsland/GSK/Dynavax  ................................ ................................ ....................  29 \n2.6 CureVac  ................................ ................................ ................................ ................................ ...........  30 \n2.7 University of Oxford  ................................ ................................ ................................ .......................  31 \n2.8 BioNTech/Fosun Pharma/Pfizer  ................................ ................................ ................................ .. 32 \n3 Results: Therapeutics  ................................ ................................ ................................ .....................  34 \n3.1 Remdesivir/GS -5734  ................................ ................................ ................................ ......................  35 \n3.2 Lopina vir + Ritonavir (Kaletra\u00ae)  ................................ ................................ ................................  42 \n3.3 Favipiravir (Avigan\u00ae)  ................................ ................................ ................................ ....................  49 \n3.4 Darunavir  ................................ ................................ ................................ ................................ ........  53 \n3.5 Chloroquine (Resochin\u00ae)  ................................ ................................ ................................ ..............  55 \n3.6 Hydroxychloroquine (Plaquenil\u00ae)  ................................ ................................ ...............................  62 \n3.7 Camostat Mesilate (Foipan\u00ae)  ................................ ................................ ................................ ....... 72 \n3.8 APN01/ Recombinant Human Angiotensin -converting Enzyme 2  (rhACE2)  .........................  73 \n3.9 Tocilizumab (Roactemra\u00ae)  ................................ ................................ ................................ ...........  75 \n3.10 Sarilumab (Keyzara\u00ae)  ................................ ................................ ................................ ...................  90 \n3.11 Interferon beta 1a (SNG001)  ................................ ................................ ................................ .........  94 \nReferences  ................................ ................................ ................................ ................................ .................  97 \n \n \nTable  0 -0: Internationale Quellen ................................ ................................ ................................ ............  8 \nTabelle 0 -2: Produkt\u00fcbersicht zu Covid -19 Medikamenten (fortgeschrittene Entwicklungsstadien) \n(n=11)  ................................ ................................ ................................ ................................ .............  11 \nTabelle 0 -3: Produkt\u00fcbersicht zu fortgeschrittenen Impfstoffprojekten  ................................ ............  18 \nTable 1.2 -1: International Sources  ................................ ................................ ................................ ..........  24 \nTable 2 -1: Most advanced vaccines in the R&D pipeline  ................................ ................................ ..... 25 \nTable 2.1 -1: mRNA -1273 in clinical trial registry  ................................ ................................ .................  26 \nTable 2.2 -1: Ad5 -nCoV in clinical trial registry  ................................ ................................ ....................  27 \nTable 2.3 -1: Information on INO -4800  ................................ ................................ ................................ ... 28 \nTable 2.4 -1: Novavax COVID -19 Vaccine in clinical trial registry  ................................ ......................  29 \nTable 2.5 -1: Vaccine candidate for COVID -19 developed by the University of Queensland  .............  30 \nTable 2.6 -1: CureVac  ................................ ................................ ................................ ...............................  31 \nTable 2.7 -1: ChAdOx1in clinical trial registry  ................................ ................................ ......................  32 \nTable 2.8 -1: BNT -162 in clinical trial registry  ................................ ................................ .......................  33 \nTable 3 -1: Most advanced therapeutics in the R&D pipeline  ................................ ..............................  34 Inhalt  \n 6 Table 3.1 -1 : Remdesivir in clinical trial registry  ................................ ................................ ..................  37 \nTable 3.2 -1: Lopinavir plus ritonavir (Kaletra\u00ae) in clinical trial registry  ................................ ..........  43 \nTable 3.2 1: Lopinavir plus ritonavir (Kaletra\u00ae) in clinical trial registry (Continued)  ....................  45 \nTable 3.2 -2: Publication on clinical trial on lopinavir plus ritonavir (Kaletra\u00ae)  ..............................  48 \nTable 3.3 -1: Favipiravir in clinical trial registry  ................................ ................................ ...................  51 \nTable 3.4 -1: Darunavir in clinic al trial registry  ................................ ................................ .....................  54 \nTable 3.5 -1: Chloroquine in clinical trial registry  ................................ ................................ .................  56 \nTable 3.5 1: Chloroquine in clinical trial registry (Continued)  ................................ ...........................  57 \nTable 3.5 1: Chloroquine in clinical trial registry (Continued)  ................................ ...........................  59 \nTable 3.5 -2: Publications on clinica l trials on product Chloroquine  ................................ ...................  61 \nTable 3.6 -1: Hydroxychloroquine (Plaquenil\u00ae) in clinical trial registry  ................................ ............  64 \nTable 3.6 -1: Hydroxychloroquine (Plaquenil\u00ae) in clinical trial registry (Continued)  ......................  65 \nTable 3.6 -1: Hydroxychloroquine (Plaquenil\u00ae) in clinical trial registry (Continued)  ......................  68 \nTable 3.6 -1: Hydroxychloroquine (Plaquenil\u00ae) in clinical trial registry (Continued)  ......................  69 \nTable 3.6 -2: Publications on clinical trials on product Hydroxycloroquine (Plaquenil\u00ae)  ................  71 \nTable 3.7 -1 Camostat Mesilate (Foipan\u00ae) in clinical trial registry ................................ .....................  72 \nTable 3.8 -1: APN01 in clinical trial registry  ................................ ................................ ..........................  75 \nTable 3.9 -1: Tocilizumab in clinical trial registry  ................................ ................................ .................  78 \nTable 3.9 -2: Tocilizumab in clinical trial registry (Continued)  ................................ ...........................  83 \nTable 3.9 -3: Tocilizumab in clinical trial registry (Continued)  ................................ ...........................  86 \nTable 3.10 -1: Sarilumab in clinical trial registry  ................................ ................................ ...................  91 \nTable 3.11 -1: Interferon beta -1a in clinical trial registry  ................................ ................................ ...... 95   \nAm 30. M\u00e4rz 2020 wurde vom \u00f6sterreichischen Gesundheitsministerium \n(BMSG PK) und weiteren gesundheits politischen Akteur *inn en der Wunsch \nge\u00e4u\u00dfert, ein Horizon Scanning System (HSS) f\u00fcr Covid -19 Medikamente \nund Impfstoffe einzur ichten. Die E tablierung  eines solchen HSS  f\u00fcr Covid -\n19 Interventionen hat die folgenden Absichten:  \na. Fr\u00fchzeitige Information en f\u00fcr gesundheitspolitische \nEntscheidungstr\u00e4ger dar\u00fcber, welche Interventionen (Impfungen \nund Medikamente) derzeit in klinischen Studien erprobt werden und  \nb. Monitoring dieser in den n\u00e4chsten Monaten, um gegebenenfalls \neinen evidenzbasierten Einkauf zu unterst\u00fctz en. \nUm diese Aufgabe  zu erf\u00fcllen ,  \n1. wird i n einem ersten Schritt ein e auf internationalen Quellen \nbasierende Bestandsaufnahme zu Covid -19 Medikamente und \nImpfstoffe erstellt.  \n2. In einem zweiten Schritt wird eine selektive Recherche mittels \nHandsuche  in Studienregistern nach Informationen \u00fcber klinische \nStudien am Menschen und den Stand der Forschung durchgef\u00fchrt.  \n3. Diese Informationen bilden die Grundlage f\u00fcr sogenannte \n\"Vignetten\" (Kurzbeschreibungen) f\u00fcr jene Produkte, die sich bereits \nin einem \"fortgeschrittenen\" Stadium befinden.  \n4. Anschlie\u00dfend werden die Produkte hinsichtlich des Status der \nklinischen Studien bis zur Zulassung beobachtet und schlie\u00dflich auf \nNutzen und Schaden bewertet.  \nAlle Arbeitsschritte werden in enger internationaler (europ\u00e4ischer) \nZusammenarbeit durchgef\u00fchrt.  \nZus\u00e4tzlich we rden Informationen \u00fcber \u00f6ffentliche Mittel f\u00fcr die Entwicklung \nvon Medikamenten und Impfstoffen gesammelt.  \nFolglich wird der vorliegende Bericht mehreren Versionen verf\u00fcgbar sein:  \n\uf0b7 Version 1  (V1, April 2020): Bestandsaufnahme  + Vignetten f\u00fcr die \nbis dato fortgeschrittensten Produkte  \n\uf0b7 Version 2+  (V2, V3\u2026) : monatliches Monitoring und Update  \n  \n \n \n : \n Table  0-1.1: Internationale Quellen   \n \n \n \n \nDie folgenden Produkte wurden aus folgenden Gr\u00fcnden zur weiteren \nBetrachtung  (1. Suche in Registerdatenbanken und 2. Beschreibung in Form \nvon \u201eVignetten\") ausgew\u00e4hlt:  \n\uf0b7 Produkte, die sich bereits in einem \u201efortgeschrittenen\" Stadium \nbefinden , \n\uf0b7 Produkte, die am h\u00e4ufigsten in klinischen Fachzeitschriften als \npotenzielle Kandidaten diskutiert  werden.  \nDie vollst\u00e4ndige Liste  aller Produkte findet sich in Teil  2/ Part  2 Tabelle A-\n1: Impfstoffe, Tabelle A-2: Therapeutika , Tabelle A-3:EudraCT regist ry \nstudies . \nAktuell stehen keine zugelassenen Medikamente f\u00fcr C ovid--19 zur \nVerf\u00fcgung. Eine gro\u00dfe Bandbreite an antiviralen Wirkstoffen  wird derzeit auf \ndie Wirksamkeit gegen SARS -CoV -2/Covid-19 getestet. Bei einem Gro\u00dfteil \nder Wirkstoffe, die derzeit getestet werden, handelt es sich um \n\u201eRepurposing\u201c, also Medikamente, die bereits f\u00fcr andere Indikationen \n(vorrangig andere virale Infektionen) zugelassen sind.  \nInternationale Regulatoren betonen allerdings deutlich, dass robuste Evidenz \nf\u00fcr Zulassungssudien voliegen muss [2]. Die European Medicines Agency \n(EMA) begr\u00fcndete am 9. April eine eigene Covid -19 Task Force [3]. \n \nBei den Therapien f\u00fcr Patient *innen mit C ovid--19 ist zwischen \nzielgerichteten Therapeutika  (antivirale Medikamente) und \nintensivmedizinischen  Therapieans\u00e4tzen (supportive care) zu unterscheiden. \nZielgerichtete Therapeutika  richten sich gegen virale oder auch humane \nProteine oder zellul\u00e4re Prozesse, mit dem Ziel, den Vermehrungszyklus des \nVirus (Eindringen in die Zellen, Replikation in den Zelle n, Freisetzung aus \nden Zellen) zu blockieren.   \nImmunreaktionen sind bei Infizierten grunds\u00e4tzlich erw\u00fcnscht; sie d\u00fcrfen \nnur nicht so exzessiv ausfallen, dass sie in der Lunge mehr Schaden anrichten \nals helfen. Deshalb sollen in mehreren Projekten \u00fcberschie\u00dfende \nImmunreaktionen bei schwer Erkrankten ged\u00e4mpft werden  [4]. Schwere \nKomplikationen bei SARS -CoV -2 Infektionen entstehen durch eine  zu starke \nImmunantwort des K\u00f6rpers, einem sogenannten \u201e Zytokinsturm \u201c oder \n\u201ecytokine release syndrome (CRS)\u201c. Eine Blockierung dieser Immunreaktion \ndurch Immunmodulatoren  ist daher eine Therapieoption f\u00fcr Patient *innen \nmit schweren C ovid-19-bedingten Krank heitsverl\u00e4ufen. Immunmodulatoren \nsind keine zielgerichteten (Pathogen -gerichteten) Therapeutika. Allerdings \nwirken einige der derzeit getesteten Wirkstoffe gleichzeitig Pathogen -\ngerichtet und immunmodulatorisch (z.B. Chloroquin) . \n \n \n Ein stark im Fokus der klinischen Forschung stehender Wirkstoff ist \nChloroquin , das zur Therapie und Prophylaxe von Malaria sowie zu \nBehandlung von Autoimmunerkrankungen zugelassen ist. In \nZellkulturexperimenten erzielte Chloroquin eine Unterdr\u00fcckung der \nReproduktion von SARS -CoV -2. Hydroxychloroquin  ist ein Derivat von \nChloroquin mit \u00e4hnlichen Wirkweisen und Anwendungen.  \nInterferone  sind ein wesentlicher Bestandteil der nat \u00fcrlichen Immunabwehr \ngegen virale Infektionen. Die therapeutische Verabreichung zus\u00e4tzlicher \nInterferone wird in vielen klinischen Studien getestet, meist als \nKombinationstherapie  mit antiviralen Wirkstoffen.  \nMonoklonale Antik\u00f6rper  sollen gegen die Komplikationen \"Zytokinsturm\" \nbei schwerer Covid -19 Erkrankung eingesetzt werden. Die Antik\u00f6rper haben \ndas Ziel, den Coronavirus zu neutralisieren und als vorbeugende Behandlung \neingesetzt zu werden.   \nmonoklonale Antik\u00f6rper \nbei schwer infizierten \nPatient*innen   Tabelle 0 -2: Produkt\u00fcbersicht zu Covid -19 Medikamenten (fortgeschritte ne Entwicklungsstadien) (n=11)  \n \nRemdesivir ist ein k\u00fcrzlich entwickeltes Medikament mit einem breiten \nantiviralen Spektrum. Es ist bislang f\u00fcr keine Indikati on zugelassen. \nRemdesivir  h\u00e4lt \u201eorphan drug designat ion\u201c (EMA, FDA) f\u00fcr die Indikation \nEbola. In vitro zeigt es Wirkung gegen verschiedene Viren, inklusive SARS -\nCoV, MERS -CoV und andere humane und zoonotische Coronaviren. In \nZellkulturexperimenten erzielte Remdesivir eine Unterdr\u00fcckung der \nReproduktion von SARS -CoV -2.  \nRemdesivir  wird derzeit in mehreren klinischen Studie n (7 Studien, davon 6 \nPhase III randomisierte kontrollierte Studien [ RCTs ]) untersucht, von denen \nzwei  Studien Firmenstudien von Gilead sind und weitere f\u00fcnf Studien von \n\u00f6ffentlichen Institu tionen durchgef\u00fchrt werden. Alle Studien befinden sich \nim Stadium der Rekrutierung. Die Gilead (Zulassungs -) Studien untersuchen \nRemdesivir  sowohl bei \u201emoderat\u201c Erkrankten wie bei schwer an Covid -19 \nErkrankten. Erste Ergebnisse k\u00f6nnen im Mai 2020 erwartet werden . \nErgebnisse aus den \u00f6ffentlich -finanzierten Studien k\u00f6nnten ev. auch bereits \nim April 2020 zu erwarten sein.   \n \nLopinavir  in Kombination mit Ritonavir  ist seit 2000 (FDA), resp. 2001 \n(EMA ) f\u00fcr die Therapie von HIV zugelassen, nicht jedoch f\u00fcr Covid -19. Die \nersten Ergebnisse eine m RCT  mit Patient *innen mit C ovid-19 wurden am \n18.03.2020 publiziert  [5]. Die Behandlung von Patient *innen mit der \nKombination zweier anti -HIV Medikamente Lopinavir  + Ritonavir \n(zus\u00e4tzlich zur Standardbehandlung) erzielte keine Verbesserung  in Bezug \nauf die Dauer bis zur Genesung im Vergleich zur Standardbehandlung. Die \nRate an Patient *nnen mit detektierbarer viraler RNA unterschied sich nicht  \nzwischen den beiden Gruppen, woraus die Autor *innen schlie\u00dfen, dass der \ngrundlegende er w\u00fcnschte Effekt der Kombinationstherapie \u2013 Inhibierung \nder viralen Reproduktion \u2013 nicht erzielt wurde [5]. Elf weitere Studien laufen \nzur Z eit (10 RCTs, 9 davon in China, 1 in Frankreich, 1 in Kanada, alle \n\u00f6ffentlich finanziert). Die fr\u00fchsten Ergebnisse von zwei  Studien sind im \nSommer 2020 zu erwarten.  \nFavipiravir wurde 1999 von einer japanischen Pharmafirma als \nGrippemedikament (Handelsname: Avigan) entwickelt. Es h\u00e4lt keine EMA -\nZulassung. Favipiravir wurde in Einzelf\u00e4lle gegen Ebola eingesetzt. Im \nFebruar 2020 wurde Favipiravir in China in einer ersten  nicht \nrandomisierten Doppelblindstudie (nRCT) an 80 Patient *inn en als antivirale \nTherapie gegen das Coronavirus SARS -CoV -2 getestet.  Favipiravir wird \nderzeit in mehreren klinischen S tudie n (1 abgeschlossene  kontrollierte \nStudie , 3 laufende RCTs und 1 laufender nRCT)  untersucht, von denen alle \nStudien von \u00f6ffentlichen Institutionen (nur China) durchgef\u00fchrt werden. \nVier Studien befinden sich im Stadium der Rekrutierung  oder noch davor . \nDie abgeschlossene Studie wird demn\u00e4chst (nach peer -review) ver\u00f6ffentlicht. \nErste Ergebnisse k\u00f6nnen im April/ Mai 2020 erwartet werden . \nDarunavir  ist seit 200 6 (FDA), resp. 200 7 (EMA ) f\u00fcr die Therapie von HIV \nzugelassen, nicht jedoch f\u00fcr Covid -19. Derzeit laufen zwei  RCTs (in China), \neine Studie rekrutiert, die andere noch nicht. Ergebnisse sind erst ab \nDezember 2020 zu erwarten.  \nChloroquin Phosphate  und Hydroxychloroquin  sind seit den 7 0er Jahren  als \nArzneistoff e zur Therapie  und Chemoprophylaxe  von Malaria sowie zu \nBehandlung von Autoimmunerkrankungen zugelassen. Die FDA verf\u00fcgte \nj\u00fcngst eine \u201eemergency use authorization for Covid -19\u201c, nicht jedoch die \nEMA . Chloroquin Phosphate und Hydroxychloroquin  (als \nKombinatinstherapie mit Azithromycin) wird jedoch \u2013 aufgrund der \nNebenwirkungen - ausschlie\u00dflich  bei schweren Kra nkheitsverl\u00e4ufen \nempfohlen, nicht als Prophylaxe bis valide Evidenz vorliegt [6, 7]. \n F\u00fcr Chloroquin  Phosphate  (als Monotherapie oder als Kombinationstherapie \nmit Lopinavir + Ritonavir )sind 11 klinische Studien (alle in China, alle \n\u00f6ffentlich finanziert , 8 davon kontrolliert Phase VI , rekrutierend ) zur \nEffektivit\u00e4t von Chloroquin mit hospitalisierten Patient *innen mit schwerer \nCovid-19 Erkrankung registriert. In der einzigen ver\u00f6ffentlic hten Studie [8] \nan 22 Patient*innen wird von einem kleinen Nutzen berichtet. Erste \nErgebnisse von gr\u00f6\u00dferen Studien sind ab Fr\u00fchsommer und He rbst 2020 zu \nerwarten.   \nDerzeit laufen 15 klinische Studien (8 kontrolliert e Phase IV  in China, 5 \nPhase III RCTs , alle \u00f6ffentlich finanziert ) zu Hydroxychloroquin  (als \nMonotherapie oder als Kombinationstherapie mit Lopinavir + Ritonavir ) zu \nPatient*innen mit verschiedenen Schweregraden der Covid -19 Erkrankung. \nDie in China registrierten Studien zur Effektivit\u00e4t von Hydroxychloroquin \nmit Patient *innen mit C ovid-19 registriert \u00fcberschneiden sich teilweise mit \nden Studien zu Chloroquin.  \nIn einer nRCT  in Frankreich wurden 70 % der Patient *nnen mit C ovid-19, \ndie mit Hydroxychloroquin behandelt wurden (n=20) nach sechs Tagen \nvirus -frei gete stet. Im Vergleich dazu wurden nur 12,5 % der C ovid-19 \nPatient *innen in einer nicht n\u00e4her definierten Kontrollgruppe nach sechs \nTagen virus -frei getestet . Die Studie weist allerdings mehrere \nschwerwiegende methodische M\u00e4ngel auf. In China sind 12 klinische  Studien \nzur Effektivit\u00e4t von Hydroxychloroquin mit Patient *innen mit C ovid-19 \nregistriert (diese \u00fcberschneiden sich teilweise mit den Studien zu \nChloroquin). Weitere Ergebnisse sind ab Mai 2020 zu erwarten.  \nCamostat  ist ein Wirkstoff aus der Gruppe der Protease -Inhibitoren, der \nunter anderem bei einer Entz\u00fcndung der Bauchspeicheldr\u00fcse und einer \npostoperativen Reflux\u00f6sophagitis eingesetzt wird  (Zulassung nur in Japan , \nnicht von EMA, FDA ). Weil Camostat die Protease TMPRSS2 hemmt, welche \nf\u00fcr das Eindringen von SARS -CoV -2 in die Wirtszellen wichtig ist, wurde das \nArzneimittel im Jahr 2020 f\u00fcr die Behan dlung von Covid -19 untersucht.  \nDerzeit ist nur ein RCT (D\u00e4nemark, \u00f6ffentliche Finanzierung) registriert. \nEin Ergebnis ist mit Dezember 2020 zu erwarten.  \nDas Medikament APN01  ist aus der SARS -Forschung hervorgegangen und \nwurde zwischenzeit lich auch schon in Patient *inn enstudien gegen andere \nLungenerkrankungen erprobt. APN01  hat derzeit keine Zulassung, weder \nvon E MA, noch von FDA. Es blockiert ein Molek\u00fcl auf  Viren, das diese zum \nEindringen in Lungenzellen ben\u00f6tigen und hilft zus\u00e4tzlich dabei, \nLungensch\u00e4den durch Entz\u00fcndungsreaktionen zu vermeiden.  \nAPN01  wird derzeit in einem Phase II RCT klinisch untersucht; die \nRekrutierung hat aber noch nicht begonnen. Erste Ergebnisse sind im \nNovember 2020 zu erwarten.   \nStudie aus FR mit \nschweren methodische n \nM\u00e4ngel n: Behandlung \nerfolgreich  \n \nweitere Ergebnisse: ab \nMai 2020  \n \nTocilizumab ist ein monoklonaler Antik\u00f6rper, der auf den Interleukin -6-\nRezeptor abzielt. Er ist u.a. f\u00fcr die rheumatoide Arthritis zugelassen (EMA -\nZulassung : 2009) , nicht ab er bei Covid -19. Derzeit  existieren vorl\u00e4ufige \nErgebnisse einer unkontrollierten, retrospektiven Studie bei 20 \nPatient *inn en mit schwerer  Covid-19-Erkrankung und erh\u00f6hten IL -6-\nSpiegeln.   \nTocilizumab wird derzeit in 16 klinischen Studien (9 Phase II zum Tei l RCTs, \naber auch einarmigen Studien , weiter Phase IV Studien , zumeist \u00f6ffentlich \nfinanziert, Europa und USA ) erprobt , die meisten Studien sind allerdings \nnoch im Stadium der Rekrutierung . In Italien ist eine Studie mit \nPatient *inn en mit C ovid-19 und erh\u00f6h ten IL -6-Spiegeln angelaufen. Erste \nErgebnisse sind Mitte 2020 zu erwarten.  \nSarilumab  ist ebenfalls ein humaner monoklonaler Antik\u00f6rper gegen den \nInterleukin -6-Rezeptor, der zur Behandlung von rheumatoider Arthritis \nentwickelt wurde (EMA -Zulassung 2017) . \nSarilumab  wird derzeit in f\u00fcnf klinischen Studien  (Europa, USA und Kanada, \n3 Phase II/  III RCTs, 2 Phase II RCTs, 2 davon von Sanofi/ Regeneron \nPharmaceuticals finanziert) erprobt, die meisten Studien sind allerdings noch \nim Stadium der Rekrutierung . Erste Ergebnisse sind erst 2021 zu erwarten.  \nInterferone sind Varianten k\u00f6rpereigener Botenstoffe, die gentechnisch \nhergestellt werden. Sie bek\u00e4mpfen nicht die Viren, sondern f\u00f6rdern die \nk\u00f6rpereigene Virenabwehr. Zwei INFb  Pr\u00e4parate (Rebif \u00ae und Avonex \u00ae, \nEMA -Zulassung 90er Jahre) sind bei Multipler Sklerose zugelassen.  \nINFb wird derzeit in  vier klinischen Studien (Phase II, III und IV, 3 RCTs \nund 1 Beobachtungsstudie, 1 firm enfinanzierte Studie/Synairgen) erprobt. \nDie meisten Studien sind noch im Stadium der Rekrutierung.  Erste \nErgebnisse sind erst 2021 zu erwarten.  \n \n \n \n \n  \nAktuell steht kein Impfstoff zum Schutz vor C ovid-19 zur Verf\u00fcgung.  \nEs gibt allerdings eine Vielzahl von Projekten in der Entwicklungsphase. Es \nwerden zwischen 48 [4], 50 [9], 54 (Vorarbeiten  der Gesundheit \u00d6sterreich \nGmbH [G\u00d6G] ) und 79 (Teil 2 dieses Berichts)  Impfstoffprojekte  genannt, die \nauf unterschiedlichen Plattformen aufbauen z. B. DNA, RNA, Proteinen oder \nVektor -Impfstoffe. Die Unternehmen und Forschungsi nstitute arbeiten auf \nunterschiedliche Impfstoffe hin. Die meisten ihrer Projekte zielen dabei auf \neine der folgenden drei Impfstoff arten ab: \nLebendimpfstoffe mit Vektorviren : Bei mehreren Projekten dienen gut \nbekannte, harmlose Viren als Ausgangspunkt. Vektorviren sind intakte Viren, \ndie allerdings keine Krankheit hervorrufen k\u00f6nnen. Diese harmlosen Viren \nwerden \u201everkleidet \u201c, im aktuellen Fall als SARS -Cov-2. Dazu werden mittel s \nGenschere  Oberfl\u00e4chenproteine des neuen Coronavirus eingef\u00fcgt, damit das \nmenschliche Immunsystem einen Schutz dagegen aufbaut  [10]. Aufbauend \nauf einem Vektorvirus sind auch der erste zugelassene Ebola -Impfstoff, ein \nweiterer Ebola -Impfstoff (dessen Zulassung beantragt is t) und weitere \nexperimentelle Impfstoffe entwickelt worden. Diese Strategie kommt nun \nbeispielsweise in den Covid -19-Projekten von Janssen , dem Deutschen \nZentrum f\u00fcr Infektionsforschung (DZIF ) und der University of Oxford  zur \nAnwendung [4].  \nTotimpfstoffe mit Virusproteinen : Mehrere Projekte, die auf Impfstoffe mit \nVirusproteinen abzielen (wie etwa die von Novavax , Greffex  und der \nUniversity of Queensland ), beruhen auf lang bew\u00e4hrter Technologie: Sehr \nviele zugelassene Impfstoffe sind zusammengesetzt; beispielsweise solche \ngegen Tetanus, Hepatitis B oder Grippe . Totimpfstoffe enthalten \nVirusproteine  (nicht-replizierender viraler Vektor ), die eine Immunantwor t \nausl\u00f6sen, ohne dass dabei durch das Virus ein Krankheitsgeschehen bei einem \nMenschen ausgel\u00f6st wird [4]. \nGenbasierte Impfstoffe : Zum anderen gibt es auch neue Ideen f\u00fcr Impfstoffe, \ndie auf DNA oder mRNA basieren. Diese Impfstoffe enthalten ausgew\u00e4hlte \nGene des Virus in Form von mRNA1 bzw. DNA , sodass im menschlichen \nK\u00f6rper Virusproteine gebildet werden, die dann wiederum zur Immunit \u00e4t \nf\u00fchren. Zu den Unternehmen, die solche Impfstoffe gegen Covid -19 \nentwickeln, geh\u00f6ren CureVac , BioNTech , Moderna , Inovio , Arcturus  und \nLineaRx/Takis ; auch das OpenCorona Konsortium  entwickelt einen DNA -\nbasierten Impfstoff  [4]. \n                                                             \n1 Als mRNA (messenger RNA), auch Boten -RNA genannt, wird das einzelstr\u00e4ngige \nRNA -Transkript eines zu einem Gen geh\u00f6rigen Teilabschnitts der DNA bezeichnet.  \n \n \nNeue Technologie n und Vorerfahrung en mit Im pfstoffprojekten gegen \nverwandte Viren (siehe zuvor ) machen eine enorme Beschleunigung m\u00f6glich. \nDas belegen die Zwischenst\u00e4nde, die einige Unternehmen und \nForschungsgruppen f\u00fcr ihre Projekte gemeldet haben. Die Projekte, die \nschon am weitesten vorangekommen sind, sind bereits in Etappe 4 bzw. Phase \n1 eingetreten - der Erprobung mit Freiwilligen - oder sie planen, das in den \nkommenden Monaten zu tun.  \nTabelle 0 -3: Produkt\u00fcbersicht zu fortgeschrittenen Impfstoffprojekten  \nEine erste klinische Studie mit einem mRNA -Impfstoff  gegen SARS -CoV -2 \nist am 16.03.2020  in Seattle angelaufen. Die von der US -Firma Moderna  mit \ndem U.S. National Institute of Allergy and Infectious Diseases  entwickelte \nVakzine mRNA -1273  enth\u00e4lt die Bauanleitung f\u00fcr die Konfiguration des \nviralen Spike -Proteins, die vor Andocken des Virus an die Zelle vorliegt. Das \nKaiser Permanente Institute  verabreicht seit 16.03.2020  45 gesunden \nProband *innen Spritzen in zw ei 28 Tage auseinanderliegenden Dosen. Diese \nPhase -1-Studie  (NCT04283461 ) soll zun\u00e4chst testen, ob die Vakzine \nvertr\u00e4glich und sicher sind [11]. \n  \n \nLaut Medienberichten erlaubte China dem chinesischen Unternehmen \nCanSinoBIO die klinischen Tests ihres Mittels  Ad5-nCoV,  die mit 108 \nTestpersonen am Tongji Hospital in Wuhan durchgef\u00fchrt werden. Der \nImpfstoffkandidat von CanSinoBIO ist damit der erste neuartige \nCoronavirus -Impfstoff gegen Covid -19 in einer klinischen Phase -1-Studie in \nChina  (ChiCTR2000030906 ) und basiert auf CanSinoBIOs Adenovirus -\nbasierter Technologieplattform f\u00fcr virale Vektorimpfstoffe. Ad5 -nCoV ist ein \ngentechnisch ver\u00e4nderter Impfstoffkandidat mit dem replikationsdef ekten \nAdenovirus Typ 5 als Vektor zur Expression des SARS -CoV -2-Spike -Proteins. \nErgebnisse aus pr\u00e4klinischen Tierstudien mit Ad5 -nCoV zeigen, dass der \nImpfstoffkandidat in Tiermodellen eine starke Immunantwort ausl\u00f6sen kann. \nPr\u00e4klinische Tiersicherheitsstu dien zeigten ebenfalls ein gutes \nSicherheitsprofil [12]. \nAuch e in Forschungsteam am Jenner Institute der Universit\u00e4t Oxford  (UK)  \narbeitet gemeinsam mit dem  italienischen Hersteller Advent Srl  an der \nEntwicklung  eines Coronavirus -Impfstoff s. Noch im April 2020  soll mit \nklinischen Tests  des Impfstoffkandidaten ChAdOx1  am Menschen begonnen  \nwerden.  Der Impfstoff wird  unter Verwendung einer sicheren Version eines \nAdenovirus  hergestellt. Das Adenovirus wurde so modifiziert, dass es sich \nnicht im K\u00f6 rper vermehren kann, und der genetische Code zur Bereitstellung \nvon Anweisungen f\u00fcr die Herstellung des Coronavirus -Spike -Proteins wurde \nhinzugef\u00fcgt, damit das Adenovirus dieses Protein nach der Impfung \nproduzieren kann. Dies f\u00fchrt zur Bildung von Antik\u00f6rp ern gegen das Spike -\nProtein  (S-Protein) , das sich auf der Oberfl\u00e4che von Coronaviren befindet \n[13]. \nLaut eine Press eaussendung plant  Inovio  (USA) mit dem Wistar Institute  \n(USA) und Beijing Advaccine Biotechnology  (CHN ) im April 2020  mit \nklinischen Studien  f\u00fcr ihren DNA -Impfstoffkandidaten INO -4800  an 30 \ngesunden Freiwilligen  in den USA und bald darauf in China und S\u00fcdkorea \nzu beginnen . Der ver\u00f6ffentlichte Zeitplan sieht vor, die Ergebnisse der \nClinical Trials im Herbst 2020 zu ver\u00f6ffentlichen [14, 15]. Die Plattform von \nInovio  liefert die optimiert e DNA in Zellen, wo sie in Proteine \u00fcbersetzt wird, \ndie das Immunsystem eines Individuums aktivieren, um eine robuste gezielte \nT-Zell- und Antik\u00f6rperantwort zu erzeugen. Inovio  zielt darauf ab, das \ntherapeutische Spektrum monoklonaler Antik\u00f6rper mit seiner  DNA -\nkodierten monoklonalen Antik\u00f6rpertechnologie signifikant zu erweitern [16]. \nDas amerikanische Unternehmen  Novavax  testet derzeit mehrere \nImpfstoffkandidaten in pr\u00e4klinischen Studien und plant ab Mai oder Juni \n2020 mit der Erprobung am Menschen zu beginnen. Die Impfstoffkandidaten \nvon Novavax  wurden mit der hauseigenen Plattform f\u00fcr rekombinante \nProtein -Nanopa rtikel -Technologie entwickelt, um Antigene zu erzeugen, die \nvom Coronavirus -Spike (S) -Protein abgeleitet sind. Novavax  wird \n voraussichtlich auch seine Matrix -M\u2122-Adjuvantien2 verwenden, um die \nImmunantwort des Impfstoffkandidaten zu verbessern (Novavax 202 0). \nNovavax  erh\u00e4lt von der Coalition for Epidemic Preparedness Innovations \n(CEPI)  (siehe 0) eine Anfangsfinanzierung in H\u00f6he von 4 Mio. USD, um die \nEntwicklung eines Covid -19-Impfstoffs zu unterst\u00fctzen. Es wurde (noch) \nkein Name f\u00fcr den Impfstoffkandidaten von Novavax  ver\u00f6ffentlicht.  \nIn Australien untersucht die Universit\u00e4t Queensland  mit dem Unternehmen \nDynavax  und GSK , die Adjuvantien beisteuern, das Potenzial eines \nImpfstoffs mit genetisch ver\u00e4nderten Virusproteinen, wodurch ei ne \nImmunreaktion verst\u00e4rkt werden soll  (The Guardian 2020) . Die Erprobung \nam Menschen soll laut Medienberichten im Juni 2020  beginnen. Auch die \nUniversit\u00e4t Queensland  wird von der Coalition for Epidemic Preparedness \nInnovations (CEPI)  finanziell unterst\u00fctzt. Es  wurde (noch) kein Name f\u00fcr \nden Impfstoffkandidaten der Universit \u00e4t Queensland  ver\u00f6ffentlicht.  \nDas deutsche Biote chnologie -Unternehmen CureVac  forscht ebenfalls an \neinem  Protamin -komplexgebundenen  mRNA -basierten Impfstoffkandidaten  \n[17]. Nach eigenen Angaben habe das Unternehmen zwei Varianten eines \nImpfstoffs ausgew\u00e4hlt, die sich in Produktion bef\u00e4nden . Phase -1-Studien \nsollen laut Berichten im Juni oder Juli 2020  start en, um die Variante mit der \nbesten Wirkung zu finden.  Ende Januar  2020 erhielt Curevac von CEPI eine \nF\u00f6rderung in H\u00f6he von bis zu 8,3 Mio. Euro  f\u00fcr die beschleunigte \nImpfstoffentwicklung und -herstellung sowie f\u00fcr klinische Studien [18]. Die \nEurop\u00e4ische n Kommision  investiert 80 Mio. Euro f \u00fcr Forschung & \nEntwicklung f\u00fcr das  Unternehmen sowie die Produktion ei nes Impfstoffs. \nDie Finanzierung wird als Darlehen der Europ\u00e4ischen Investitionsbank \n(EIB) zur Verf\u00fcgung gestellt [19, 20]. \nDas Mainzer Unternehmen  BioNTech  entwickelt  gemeinsam mit dem \nchinesischen Partner Fosun Pharma  sowie Pfizer  in den USA den mRNA -\nbasierten Impfstoffkandidaten BNT162 . BioNTech beabsichtigt, \nvorbehaltlich der beh\u00f6rdlichen Genehmigung, die klinische Studie des \nProduktkandidaten BNT162 Ende April 2020 in China  zu beginnen. BNT162  \nist auch der erste Produktkandidat des Projekts  Lightspeed , BioNTechs  \nbeschleunigtes Entwicklungsprogramm, das die Pr\u00e4vention und Behandlung \nvon C ovid-19-Infektionen umfasst. F\u00fcr das Programm nutzt BioNTech  \ngemeinsam mit dem P artner Polymun  die eigenen mRNA -Plattformen  f\u00fcr \nInfektionskrankheiten  sowie  die unternehmenseigene GMP -zertifizierte \nInfrastruktur f\u00fcr die mRNA -Impfstoffherstellung  in Europa  [21].  \n                                                             \n2 Adjuvantien sind \"Wirkverst\u00e4rker\" f\u00fcr Impfstoffe, die es unter anderem erm\u00f6glichen \nk\u00f6nnen, dass wes entlich weniger Virusprotein pro Impfinjektion f\u00fcr eine \nImmunisierung ausreichen bzw. mit einer gegebenen Menge produziertem \nVirusprotein mehr Injektionsdosen hergestellt werden k\u00f6nnen.  \n \nBereits am 30. Januar 2020 ver\u00f6ffentlichte die Europ\u00e4ische Kommission \neinen Aufruf zur Interessenbekundung im Rahmen des Horizon 2020  EU-\nForschungsrahmenprogramms mit dem Titel \u201eSC1 -PHE -CORONAVIRUS -\n2020: Fort schrittliche Erkenntnisse f\u00fcr die klinische und gesundheitliche \nReaktion auf die COVID -19-Epidemie\u201c, mit einem Budget von 10 Mio. Euro, \ndas in der Folge auf 47,5 Mio. Euro aufgestockt wurde. 17 Forschungsprojekte \nmit 136 Forschungsteams aus EU -Mitgliedstaa ten und anderen europ\u00e4ischen \nL\u00e4ndern kamen in die engere Auswahl f\u00fcr eine Finanzierung und arbeiten \ninnerhalb der Teilbereiche Epidemiology (inkl. Pandemic Modelling), \nDiagnostics, Treatment sowie Vaccines, um Kenntnisse zum Coronavirus \n(SARS -CoV -2) zu ver bessern und um das klinische Management von \nPatient *innen, die mit dem Virus infiziert sind, effizienter zu gestalten. F\u00fcr \nden Teilbereich Vaccines wurden folgende Projekte ausgew\u00e4hlt  [20]: \n\uf0b7 OpenCorona mit dem Titel  \u201eRapid  therapy development through \nOpen Coronavirus Vaccine Platform \u201c; gef\u00fchrt vom schwedischen \nKarolinska Institutet  in Kooperation mit sieben Partnern au s DE, IT  \nund SE (5). \n\uf0b7 PREVENT -nCoV  mit dem Titel \u201ePrevention of 2019 nCoV infection  \nthrough development and clinical testing of a novel Virus Like Particle \n(VLP) vaccine\u201d; gef\u00fchrt vom d\u00e4nischen AdaptVac  in Kooperation mit \nsechs  Partnern aus DE, DK  (3) und NL (2). \nZudem werden m ehrere Impfstoffprojekte von  der Coalition for Epidemic \nPreparedness Innovations (CEPI)  finanziell unterst\u00fctzt . \nDie Coalition for Epidemic Preparedness Innovations (CEPI)  wurde 2017 von \nmehreren staatlichen und nicht -staatlichen Geldgebern als Reaktion auf die \nEbola -Krise 2014 gegr\u00fcndet.  Die weltweite Allianz in \u00f6ffentlich -privater \nPartnerschaft zwischen  Staaten3, Stiftungen (u.a. die Bill & Melinda Gates \nFoundation und der Wellcome Trust), Forsch ungseinrichtungen , \nPharmaunternehmen , der WHO sowie der EU -Kommission , hat den  Aufbau \neines Forschungsnetzwerks zur Erforschung und Entwicklung neuer \nImpfstoffe zur besseren und direkteren Reaktion auf eventuell bevorstehende \nAusbr\u00fcche neuer viraler Infekt e zum Ziel. Mit Stand 23.03.2020 co -finanziert \nCEPI acht Forschungsprojekte  zur Entwicklung von Impfstoffen gegen \nCovid-19 [22, 23]: \n1. Konsortium gef\u00fchrt von Institut Pasteur  (FR) gemeinsam mit \nThemis Bioscience  (AT) und der University of Pittsburgh  (USA), 4,9  \nMio. USD , pr\u00e4klinische Phase , \n2. Moderna  (USA) mit dem U.S. National Institute of Allergy and \nInfectious Diseases, Phase I , \n                                                             \n3 Norwegen, UK, Deutschland, Japan, Kanada, \u00c4thiopien, Australien, Bel gien, \nD\u00e4nemark, Finnland  \n 3. Inovio  Pharmaceuticals  (USA) mit dem Wistar Institute  (USA) und \nBeijing Advaccine Biotechnology  (CHN), 65  Mio. USD, pr\u00e4klinische \nPhase , \n4. NovaVax  (USA), pr\u00e4klinische Phase , \n5. CureVac  (DE), 42,3  Mio. USD , pr\u00e4klinische Phase , \n6. University of Hong Kong  (CHN), 0,6 Mio.  USD , pr\u00e4klinische Phase , \n7. University of Oxford  (UK), pr\u00e4klinische Phase , \n8. University of Queensland  (AUT ) mit dem Unternehmen Dynavax  \nund GSK , die Adjuvantie n beisteuern, 10,6  Mio.  USD , pr\u00e4klinische \nPhase . \nDas OpenCorona  Konsortium, das von dem  schwedischen  Karolinska \nInstitutet  gef\u00fchrt wird, hat als Erstes den Horizon 2020 EU -Zuschuss f\u00fcr ihr \nImpfstoffprojekt im Gesamtwert von 3  Mio.  Euro erhalten. Die Mitglieder des \nKonsortiums sind das  Universit\u00e4tsklinikum Karolinska, Cobra Biologics, \nAdlego AB, FoHM  (The Public Health Agency of Sweden),  IGEA Clinicla \nBiophysics, Svenska Vaccinfabriken Produktion AB  and Universit\u00e4t  Giessen . \nMit diesem Zuschuss hat die Forschungsgruppe des Impfstoffprojekts einen \ngro\u00dfen Teil der Finanzierung f\u00fcr die Entwicklung  eines Impfstoffkandidaten \ngegen das Coronavirus und die Durchf\u00fchrung einer klinischen Phase -I-\nStudie erhalten. Der Professor und Leiter der Abteilung f\u00fcr Labormedizin \ndes Karolinska  Institutet  Matti  S\u00e4llberg vermutet, dass sie \nh\u00f6chstwahrscheinlich einen  DNA-Impfstoff  entwickeln werden, da man aus \nErfahrung wisse, dass diese stabil sind und die Infrastruktur bereits \nvorhanden ist, um Millionen Dosen dieses Impfstofftyps herzustellen [24]. \nAls DNA -Impfstoff wird das Plasmid an den Muskel des Patienten/der \nPatientin abgegeben, der dann ein virales Antigen produziert, gegen das das  \nImmunsystem reagiert. Derzeit stehen aber noch mehrere \nImpfstoffkandidaten in den Gefrierschr\u00e4nken der Abteilung  f\u00fcr \nLabormedizin zur Verf\u00fcgung. Die Forscher/ -innen planen, Ende M\u00e4rz 2020 \nmit parallelen Tests an Tiermodellen zu beginnen. Die ersten Versuche am \nMenschen werden voraussichtlich im Jahr 2021 beginnen und am  \nUniversit\u00e4tsklinikum  Karolinska  stattfinden  [25]. \n \nDas PREVENT -nCoV  Konsortium hat ebenfalls den Horizon 2020 EU -\nZuschuss mit einem Gesamtwert von 2,7  Mio.  Euro erhalten und setzt die von \nAdaptVa c (DNK)  entwickelte  universal viral Capsid -like Particle (CLP) \nTechnologie sowie ExpreS2ion\u2019s non -viral Drosophila S2 cells expression \nsystem ein, um einen optimalen Impfstoff gegen das SARS -CoV -2-Virus zu \nliefern. Die Mitglieder des Konsortiums sind  Adapt Vac (Lead) ; Institut f\u00fcr \nTropenmedizin  (ITM) der Universit\u00e4t T\u00fcbingen; Abteilung f\u00fcr Medizinische \nMikrobiologie des  Universit\u00e4tsklinikums Leiden (LUMC);  Abteilung f\u00fcr \nImmunologie und Mikrobiologie der  Universit\u00e4t Kopenhagen; ExpreS2ion \nBiotechnologies; und das Labor f\u00fcr Virologie  der Wageningen Universit\u00e4t. \nDas Ziel besteht darin, dass der Impfstoff die ersten klinischen Tests am \nMenschen abschlie\u00dft, um die Sicherheit  und Wirksamkeit innerhalb von 12 \nMonaten nachzuweisen  [26].  \n \n \n \n  \n \n \nOn March 30th 2020, a request  was raised by the Austrian Ministry of Health  \n(BMASGK) and further Austrian policy stakeholde r to set up a Horizon \nScanning ystem (HSS) for medicines and vaccines. The establishment of a \nHSS/ Horizon Scanning System  for Covid -19 interventions has the intentions \nof  \na. informing health policy makers at an early stage which interventions \n(vaccinations and drugs) are currently undergoing clinical trials and  \nb. monitoring them over the next few months in order to support \nevidence -based purchasing, if necessary.  \n \nTo respond to this request,  \n9. As a first step an inventory, based on international source s, is built.  \n10. As a second step, selective searches by means of searches in study \nregistries are carried out for information on clinical studies in \nhumans and the state of research.    \n11. This information forms the basis for \u201cvignettes\u201d (short descriptions) \nfor those products that are already  in an \"advanced\" stage.    \n12. Subsequently, the products are monitored with regard to the status \nof the clinical studies up to approval and finally evaluated for their \nbenefit and harm.  \nAll work steps are conducted in close international (European) cooperation.  \nAdditionally, public funding for the development of medicines and vaccines \nis gathered.  \n\uf0b7 Version 1(V1 , April 2020 ): inventory  + vignettes for most advanced  \n\uf0b7 Version 2+: monthly monitoring and updates  \nmultistep approach:  \n \ninventory  \nselective searches  \nvignettes  \nmonitoring  \n(European) cooperation  \nadditional: monitoring \nof public funding R&D  \nV1: inventory + \nvignettes  \nV2: monthly monitoring   \n \n \n  Table 1.2-1: International  Sources  \n \nThe following products have been selected for further investigation (searches \nin registry databases and description as \u201cvignettes\u201d) for the following reasons:  \n\uf0b7 most advanced in clinical research ins humans  \n\uf0b7 most  often discussed in clinical journals as potential candidates  \nThe full inventory (list) can be found in Part 2 - Appendix A -1: vaccines, A -2, \ntherapeutics , A3-EudraCT registry studies.   \n \n \n  \n \nTable 2 -1: Most  advanced vaccines in the R&D pipeline  \n \n \n \n  \n \nAbout the vaccine  \nThe \n vaccine candidate developed by ModernaTX, Inc. in collaboration with NIAID and \nsponsored by NIAID/CEPI is an LNP -encapsulated mRNA -based vaccine (mRNA -1273) intended for \nprevention through full -length , perfusion stabilized spike (S) protein of SARS -CoV -2 that is the key into \nthe human cell  [27]. An mRNA -based v irus has not been approved for use in humans yet [28]. \nEstimated timeline for approval  \nCurrently, this is the first ongoing phase I trial with 45 healthy participants. It takes place in three centres \nin the US where the participants are split to 3 groups where they receive two injections of low  (25 mcg) , \nmedium  (100 mcg)  or high doses (250 mcg) of mRNA -1273 and are monitored for any AEs and immune \nresponse  [29]. Safety reviews are in place before dose escalation [29].  The primary endpoint of the study \nis frequency and grade of adverse reactions at 7/28/394 days post injection  [27]. The se condary endpoints \nmeasure the level of antibodies at 57 days post injection. The Phase I safety study should be completed by \nJune 2021.  \nTo date, no completed studies in humans are available for mRNA -1273.  \nTable 2.1-1: mRNA -1273  in clinical trial registry  \nSources: clinicaltrials.gov [27], Abbreviations: CEPI - Coalition for Epidemic Preparedness Innovations, LPN - \nlipid nanoparticle, N.A. \u2013 not applicable, NIAID - National Institute of Allergy and Infectious Diseases.  \n  \n \nAbout the vaccine  \nThe AD5 -nCoV  vaccine candidate developed by CanSino Biologics Inc . and the Beijing Institute of \nBiotechnology is a replication -defective adenovirus type 5 that expresses SARS -CoV -2 spike pr oteins. The \nvectored vaccine is intended to prevent the disease caused by the novel coronavirus  [30-32]. The platform \n(non-replicating viral vector)  of AD5 -nCoV was originally used for an Ebola vaccine (AD5 -EBOV) [32, \n33]. \nEstimated timeline for approval  \nCurrently, the first clinical, phase I trial with 108 healthy adults is ongoing. The study is a single -centre \ndose -escalation study to test both the safety and tolerability of AD5 -nCoV injections in three intervention \ngroups using different dosages (low, m edium and high). The primary endpoint of the trial is adverse \nreactions up to seven days post -vaccination. Further twelve secondary safety and immunogenetic \nendpoints are additionally measured. Data collection for the primary outcome is anticipated to fini sh in \nDecember 2020. The study is estimated to be completed in December 2022 [34].  \nTo date, no completed studies in humans are available for AD5 -nCoV.  \nTable 2.2-1\nAd5-nCoV  in clinical trial registry  \nSources: [30-34], Abbreviation: N.A. \u2013 not applicable.  \n \n  \n \nAbout the vaccine  \nThe INO -4800 vaccine candidate  developed by Inovio Pharmaceuticals Inc.  is a DNA plasmid vaccine \nbased on a DNA platform. The DNA is hereby synthesised in a laboratory, hence, no actual virus samples \nare required [33, 35]. The company\u2019s DNA platform was previously utilised for a MERS -CoV vaccine \n(INO -4700) tested in a phase I trial [15]. \nEstimated timeline for approval  \nAt this moment in time, INO -4800 is still in t he preclinical phase. According to press releases from the \nmanufacturer [14, 15], human testing (a phase I clinical trial) may start in April 2020. The results are \naimed to be presented and published thereafter (fall 2020).  \nTo date, no ongoing or completed studies in humans are available for the INO -4800 vaccine candidate.  \nTable 2.3-1: Information on INO -4800   \nSources: [14, 15, 33, 35]. Abbreviations: CEPI \u2013 Coalition for Epidemic Preparedness Innovations; N.A. \u2013 not \napplicable.  \n \nAbout the vaccine  \nThe Novavax COVID -19 vaccine being developed by Novavax and co -sponsored by CEPI [36] is a \nrecombinant protein nanoparticle technology platform  that is to generate antigens derived from the \ncoronavirus spike (S) protein  [37]. Novava x also expects to utilize its proprietary Matrix -M\u2122 adjuvant in \norder to enhance immune responses . Matrix -M\u2122 is Novavax patented saponin -based adjuvant  that has \nthe potential to boost the immune system by stimulating  the entry of antigen -presenting cells i nto the \ninjection site and enhancing  antigen presentation in local lymph nodes, boosting immune responses  [38, \n39]. \nEstimated timeline for approval  \nCurrently , Novavax has been assessing recombinant nanoparticle vaccine candidates in animal models  \nand they aim to i nitiate Phase I clinical trial in May/June 2020 [36]. Novavax has previous experience \nwith both MERS and SARS [38]. \nTo date, no completed studies in humans are available for  Novavax COVID -19 vaccine.   \nTable 2.4-1: \n in clinical trial registry  \nSources: [36, 37] Abbreviations: CEPI - Coalition for Epidemic Preparedness Innovations, N.A. \u2013 not applicable, \nVLP - virus -like particle.  \n \nAbout the vaccine  \nTogether with DynaVax and  GlaxoSmithKline (GSK)4, The University of Queensland currently \ninvestigates on a potential vaccine using molecular clamp stabilized Spike proteins [28, 33]. The so called \n\u2018molecular clamp\u2019 technology is hereby utilised: the intended p revention is through synthesising surface \nproteins and \u201eclamping\u201d them into shape. In so doing, the immune system may induce a response, by \nrecognising them as the correct antigen on the surface of the virus, more easily [40].  \nInitially, this technology was designed to be a platform for generating vaccines against different viruses \nsuch as influenza, Ebola, and the MERS coronavirus [41]. \nEstimated timeline for approval  \nAt this momen t in time, the vaccine candidate developed by the University of Queensland is still in the \npreclinical phase. According to press releases, human clinical trials may start in June 2020 [42]. \nTo date, no ongoing or completed studies in humans are available for the candidate vaccine.  \n  \n                                                             \n4 Both DynaVax  and GSK  will provide adjuvants .  \nTable 2.5-1: Vaccine candidate for COVID -19 developed by the University of Queensland  \nSources: [28, 33, 41-43]. Abbreviations: N.A. \u2013 not applicable. CEPI - Coalition for Epidemic Preparedness \nInnovations.  \n \nAbout the vaccine  \nThe vaccine candidates developed by CureVac are a protamine -complexed mRNA -based vaccine \nexpressing undisclosed SARS -CoV -2 protein(s) [28]. Each CureVac product is a tailored molecular \ncreation that contains 5\u2019 and 3\u2019  untranslated regions  and the open reading frame  to make sure translation \nof the messenger RNA (mRNA) sequence results in appropriate levels of proteins in the body [44]. This \nmeans that CureVac\u2019s technology uses mRNA as a data carrier in order to train the human body to produce \nideal levels of proteins.  Thereby the immune system is stimulated and can respond to antigens [45].  \nRecently, CureVac reported on results from an interim analysis of a Phase 1 study on a novel prophylactic \nmRNA based rabies vaccine, which showed that humans were fully protected after two doses of 1\u00b5g mRNA \nvaccine [46]. The same concept and technology that was applied in the development of this vaccine will \nalso be used for the vaccine against the the new coronavirus.  \nEstimated timeline for approval  \nDuring a press conference call on March 17, 2020, CureVac explained that  they are currently encoding 1 \nspecific protein, which is present on the surface of the new coronavirus and which is sufficient to activiate \nthe immune system. They are currently waiting for the animal data and already started with the \nproduction of 2 vacc ine candidates for use in humans [47]. Those suitable vaccine canditates were selected \nfrom several constructs. The selection criteria applied were based on quality and b iological activity. \nCureVac is also collaborating with the German Paul Ehrlich Institute (PEI) and European health \nauthorities. The start of the clinical trials is planned for early summer 2020 and it was reported that two \nprimary study centers have alread y been determined [48].  \nTo date, no ongoing or completed studies in humans are available for the vaccine candidates.  \n   \nTable 2.6-1: \n  \n\uf0b7 \n\uf0b7 \nSources: [1, 9, 19, 28, 47, 49] Abbreviations: N.A. \u2013 not applicable. CEPI - Coalition for Epidemic Preparedness \nInnovations  \n \nAbout the vaccine  \nThe ChAdOx1 nCoV -19 vaccine candidate developed by the Jenner Institute at Oxford University is based \non a non -replicating viral vector. A chimpanzee adenovirus platform is hereby used. This platform was \npreviously utilised in clinical phase I trials for a vaccine against MERS  [13, 30].  \nThe vaccine candidate uses a genetically modified safe adeno virus that may cause a cold -like illness. The \nintended prevention is through the modified adenovirus producing Spike proteins, eventually leading to \nthe formation of antibodies to the coronavirus\u2019s Spike proteins. These antibodies may bind to the \ncoronavir us and, subsequently, stop it from causing an infection [13]. \nEstimated timeline for approval  \nCurrently, the first clinical phase I/II trial in 510 healthy adults is ongoing. The study is a si ngle-blinded, \nplacebo -controlled, multi -centre randomised controlled trial to test efficacy, safety and immunogenicity \nof ChAdOx1 nCoV -19. The primary endpoints are number of virologically confirmed symptomatic \ncases/symptomatic cases of COVID -19 (efficacy ) and occurrence of serious adverse events (safety). \nPrimary endpoints are measured within six months and an optional follow -up visit is offered at day 364. \nThe study is estimated to be completed in May 2021 [50].  \nTo date, no completed studies in humans are available for  the ChAdOx1 nCoV -19 vaccine candidate . \n   \nTable 2.7-1: ChAdOx1 in clinical trial registry  \nSources: [13, 30, 33, 50]. Abbreviations: FU \u2013 follow up; N.A. \u2013 not applicable.  \n \nAbout the vaccine  \nThe BNT -162 vaccine candidate developed by BioNTech in collaboration with Focun Pharma and Pfizer \nis an mRNA platform -based vaccine expressing codon -optimized undisclosed SARS -CoV-2 protein(s) \nencapsulated in 80-nm ionizable cationic lipid/phosphatidylc holine/ cholest erol/polyethylene glycol \u2013\nlipid nanoparticles  [28]. In 2018, Pfizer and BioNTech collaborated on  mRNA -based vaccines for the \nprevention of influenza and their partnership applies outside of China [51]. BioNTech\u2019s partnership with \nFosun Pharma  applies for  China  only [51, 52]. \nEstimated timeline for approval  \nCurrently , BNT -162 is expected to enter clinical testing by the  end of April 2020  [53] and R&D is supposed \nto be carried out both in the US as well as in Germany [51]. \nTo date, no completed stud ies in humans are available for  the BNT -162 vaccine.   \n \n \n  Table 2.8-1: BNT -162 in clinical trial registry  \nSources: [28, 53]. Abbreviations: N.A. \u2013 not applicable.   \n \n \n  \n \nTable  3-1: Most advanced therapeutics in the R&D pip eline \n \n \nAbout the d rug under consideration  \nRemdesivir (RDV)/GS -5734 constitutes another potential therapeutic treatment of the 2019 novel \ncoronavirus shortly called COVID -19 or 2019 -nCoV. RDV has a broad spectrum of antiviral activities \nagainst RNA viruses. RDV is a nucleotide analogue inhibitor of RNA -dependent RNA polymerases \n(RdRps). Originally it was utilised against the severe acute respiratory syndrome -CoV (SARS -COV) an d \nthe Middle East respiratory syndrome (MERS -COV). Research has shown that RDV could effectively \ninhibit MERS -COV replication in vitro, and showed efficacy against SARS -COV in animal trials. \nFurthermore, phase 3 clinical trials of RVD examining pharmacokin etics and safety had been completed \nfor the treatment of Ebola [54]. \nIn 2020 RDV has been utilised in hundreds of COVID -19 patients in the US and Europe outside of a \nclinical trial in what is called compassionate use [55]. One case study published in the New England \nJournal of Medicine (NEJM) reports the use of RDV in a patient with COVID -19. In this case report, the \ntreatment with intravenous RVD was initiated on the evening of day 7, witho ut observation of apparent \nadverse events in association with the infusion. On the 8th day after hospitalisation (the 12th day after onset) \nthe clinical symptoms improved on the 8th day after hospitalisation [56]. \nCurrently, a major limitation is a lack of evidence with regard to efficacy and safety, i.e. lack of phase 1 \nand 2 clinical data against 201 9 novel coronavirus. The majority of studies mentioning RDV propose that \nfurther assessments of this antiviral agent is needed by clinical trials.  \nThe therapy with RVD is not approved by the European Medicine Agency (EMA) for COVID -19, but was \nrecommended on compassionate use for on the 3rd of April 2020 [57]. Furthermore, it has orphan \ndesignation for the treatment of Ebola v irus disease since February 2016. RVD is not approved by the \nFood and Drug Administration (FDA), but the use of RDV for COVID -19 was granted on the 19th of \nMarch in the course of the expanded access program to allow the emergency use, and in addition it ha s an \norphan designation for Ebola since September 2015 [58]. \nOngoing studies  \nThe search in two clinical trial registers (humans only) yielded no completed study on the safety and \nefficacy of RVD in COVID -19 patients.  Two ongoing phase 3 randomised controlled trials (RCT) to \nevaluate intravenous RVD in patients with 2019 -nCoV were i nitiated in the beginning of February in  \nChina (NCT04252664 and NCT04257656). The estimated completion date of both trials is in April 2020. \nAnother phase 3 multicentre RCT was started on the 21st of February with the estimated completion date \nin April 202 3 (NCT04280705). In addition, 3 further phase 3 multicentre RCTs that start in the first \n(NCT04292899), third (NCT04292730), and fourth (NCT04315948) week of March respectively could be \nidentified. Two of the trials are global multicentre RCTs in 96 (NCT04 292730) and 91 (NCT04292899) \ncentres respectively with completion dates in April 2020 and April 2023, and one is a multicentre trial \nconducted in 3 centres in France (NCT04315948) with the estimated completion date in March 2023. \nTable 3.1-1 displays more details of the identified ongoing trials.  \nResults of publications  \nA hand search on the 3rd of April 2020 in PubMed was conducted and gave 27 hits. So fa r no relevant \nfinished publications or finished trials assessing the efficacy and safety could be identified. First results \ncan be expected on the 10th of April 2020 (NCT04252664).   \n \n \n  Table 3.1-1 : \n  in clinical trial registry  \n                                                             \n5 RDV was recommended on compassionate use for COVID -19 (03/04/2020) by the EMA  57. European Medicines Agency (EMA). EMA pro vides recommendations on \ncompassionate use of remdesivir for COVID -19. 2020 [cited 2020 03.04.2020]; Available from: https://www.ema.europa.eu/en/news/ema -provides -recommendations -compassionate -\nuse-remdesivir -covid -19.. \n6 The use of RDV for COVID -19 was granted in the course of the expanded access program to allow the emergency use (19/03/2020) by the FDA 58. Food and Drug \nAdministration (FDA). Coronavirus (COVID -19) Update: FDA Continues to Facilitate Development of Treatments. 2020 [cited 2020 03.04.2020]; Available from: \nhttps://www.fda.gov/news -events/press -announcements/coronavirus -covid -19-update -fda-continues -facilitate -development -treatments. .  \n                                                             \n7 The entry in the clinical trial register indicates that this trial has a phase 2, as well as a phase 3 status.   \n                                                             \n8 The official trial name is (Norwegian) NOR Solidarity Multicenter Trial,  but the definite location is not reported.  \n9 The trial has three study arms, each having either Hydroxychloroquine, Remdesivir or Standard of Care as active comparator an d the other two as interventions.   \n \nNC = Not clear, NR = Not reported, RDV = Remdesivir, SOC = Standard of care   \n \n \n  \n \nAbout the drug under consideration  \nLopinavir and ritonavir are human immunodeficiency virus (HIV) protease inhibitors that are originally \nused in combination to treat HIV infection. Concerning HIV,  they work by decreasing the amount of \nHIV in the blood. An increased amount of lopinavir can be detected in the body resulting from the \ntreatment combination of both substances [30, 59]. \nThe combination therapy of lopinavir and ritonavir (Kaletra) has been approve d by the American Food \nand Drug Administration (FDA) since 15.09.2000 and by the European Medicines Agency (EMA) since \n19.03.2001 as an HIV medicine to treat adults and pediatric patients (14 days and older) with HIV -1 \ninfection.  \nDrug used in Covid -19 pati ents: ongoing studies  \nRecently, lopinavir in combination with ritonavir is also applied in patients with Covid -19 infection. \nThe search in clinical trials (humans only) yielded no completed study on the safety and efficacy of \nlopinavir plus ritonavir for C ovid-19 patients. Two ongoing phase IV randomised controlled trials \n(RCTs) (NCT04255017, NCT04252885), two ongoing phase III RCTs (NCT04315948, NCT04321174), \none ongoing phase II RCT (NCT04307693) and additional ongoing Chinese RCTs with unknown study \nphas es (ChiCTR2000029308, ChiCTR2000029387, ChiCTR2000029539, ChiCTR2000029541, \nChiCTR2000030187), as well as, one ongoing non -randomised controlled trial (NRCT) with an unknown \nstudy phase (ChiCTR2000029600) could be identified.  \nThe two phase IV RCTs are expe cted to be completed during summer 2020. One phase III study is \nexpected to be completed within one year (March 2021) and the second phase III RCT will be completed \nby March 2023. The phase II clinical study is expected to be completed within the next mont h (May \n2020). One of the Chinese RCTs was expected to be completed by the end of March 2020 and, but results \nare not available yet, and the remaining four Chinese RCTs have an estimated completion date between \nDecember 2020 and February 2021. The NRCT is e xpected to be completed by the end of April 2020. \nTable 3.2-1. \nDrug used in Covid -19 patients: results of publications  \nSo far (status: 03.04.2020) only one publication [5] on the effectiveness and safety of lopinavir in \ncombination with ritonavir in adults hospitalised with severe Covid -19 could be identified (clinical trial \nChiCTR2000029308). In the study, 199 patients were randomly assigned to lopinavir/ ritonavir (n=99) \nor standard therapies (n=100) including supplemental oxygen, noninvasive and invasive ventilation, \nantibiotic agents, vasopressor support, renal -replacement therapy, and extracorporeal membrane \noxygenation (ECMO) as necessary. Treatment with lopinavir/ ritonavir was not associated with a \nstatistically significant di fference from standard care in the time to clinical improvement (HR 1.31; 95% \nCI 0.95 -1.85, p=0.09) and the 28 -day mortality (19.2% vs. 25.0%, difference \u22125.8 percentage points; 95% \nCI \u221217.3 to 5.7, p=not reported). The percentages of patients with clinica l improvement of two points \non the 7 -category ordinal scale at day 28 (78.8 vs. 70.0, difference 8.8 percentage points, 95% CI -3.3-\n20.9, p=NR) and with detectable viral RNA at various time points were similar between the two study \ngroups. Concerning all a dverse events that occurred during the follow -up of 28 days, gastrointestinal \nevents were more common in the lopinavir/ ritonavir group, however, severe adverse events were more \nfrequently reported in the standard therapy group. Overall, no clinical benefi t could be observed with \nlopinavir/ ritonavir treatment beyond standard care in hospitalised adult patients with severe Covid -19. \nDetailed information about the study results is presented in Table 3.2-2 \n \n \n  Table 3.2-1: Lopinavir plus ritonavir (Kaletra\u00ae)  in clinical trial registry   \n \nAbbreviations: EMA \u2013 European Medicines Agency, FDA \u2013 Food and Drug Administration, Pts. - Patients  \n  \n \n \n  Table 3.2  1: Lopinavir plus ritonavir (Kaletra\u00ae)  in clinical trial registry  (Cont inued ) \n \n \nAbbreviations: EMA \u2013 European Medicines Agency, FDA \u2013 Food and Drug Administration, Pts. - Patients   \n \n \n  Table 3.2-2: Publication  on clinical trial on lopinavir plus ritonavir (Kaletra\u00ae)  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nAbbreviations: ARDS \u2013 Acute Respiratory Distress Syndrom, CI \u2013 Confidence interval, HR \u2013 Hazard ratio, ITT \n\u2013 Intionen -to-treat, NR \u2013 Not reported  \n \n \n \nAbout the drug under consideration   \nFavipiravir (Avigan\u00ae), an antiviral drug, is a new type of RNA -dependent RNA polymerase (RdRp) \ninhibitor. In addition to its anti -influenza virus activity, favipiravir is capable of blocking the replication \nof flavi -, alpha -, filo -, bunya -, arena -, noro -, and other RNA viruses and may have antiviral action against \nCovid -19 disease (caused by SARS -CoV -2, which is a RNA virus) [60, 61]. \nIn 2014, it was approved in Japan for the treatment of novel or re -emerging pandemic influenza virus \ninfections. However, use has been limited to cases, in which other influenza antiviral drugs are not \nsufficiently effective because favipiravir  was only investigated in non -clinical studies in avian influenza A \n(H5N1 and H7N9) and efficacy against seasonal influenza A or B has not been sufficiently demonstrated. \nFurthermore, favipiravir was also trialled for treating Ebola; however, evidence on t he effectiveness was \nlacking [60]. Favipiravir (Avigan\u00ae) has not been approved by the European Medicines Agency (EMA) or \nthe American Food and Drug Administration (FDA).  \nDrug used in Covid -19 patients:  ongoing studies  \nRecently, favipiravir (Avigan\u00ae) is also applied in patients with Covid -19 infection. The search in clinical \ntrials (humans only) yielded one completed multicenter, randomised, open, positive, parallel -controlled \nclinical study (ChiCTR20000 30254). Besides, three ongoing randomised controlled trials (RCTs) with \nunknown study phases (ChiCTR2000029548, ChiCTR2000029544, ChiCTR2000030113) and one ongoing \nnon-randomised controlled trial (NRCT) with an unknown study phase (ChiCTR2000029600) could be \nidentified. The three ongoing RCTs are expected to be completed between May and June 2020 and the \nongoing NRCT is expected to be completed by the end of April 2020.  \nDrug used in Covid -19 patients: results of publications  \nSo far (status: 06/04/2020), onl y one publication [62] on the co mpleted clinical trial (ChiCTR2000030254) \nabout the efficacy and safety of favipiravir to treat Covid -19 patients could be identified; however, \ncurrently the publication is available just as pre -print but not yet peer -reviewed, thus it has not been \nextract ed.  \n \n \n  Table 3.3-1: Favipiravir in clinical trial registry  \n \nAbbreviations: EMA \u2013 European Medicines Agency, FDA \u2013 Food and Drug Administration, PCR - Polymerase chain reaction, Pts. \u2013 Patients  \n  \n \n \n  Table 3.3-2: Publications on clinical trials on product favipiravir (Avigan \u00ae) \u2013 publication forthcoming  \n \nAbout the drug under consideration  \nDarunavir is an antiviral agent from the group of human immunodeficiency virus (HIV) protease \ninhibitors for the treatment of HIV -1 infections. The effects are based on the inhibition of the HIV \nprotease, which plays a central role in the maturation of the  virus and virus replication. Darunavir is \ncombined with a pharmacokinetic booster such as ritonavir or cobicistat [63]. \nDarunavir (Prezista\u00ae) has been approved by the American Foo d and Drug Administration (FDA) on the \n23th of June 2006 and by the European Medicines Agency (EMA) on the 11th of February /2007 for the \ntreatment of HIV -1 infection in adult and pediatric patients three years of age and older in combination \nwith ritonavir or other antiretroviral agents such as cobicistat. Currently, there are three generics \navailable: Darunavir K rka, Darunavir Mylan, Darunavir Krka d.d.  \nDrug used in Covid -19 patients: ongoing studies  \nRecently, darunavir (Prezista\u00ae) has also been considered as a treatment option in patients with Covid -19 \ninfection. Its inhibitory effect on SARS -CoV -2 and its potent ial therapeutic effect may be mainly due to \nits inhibitory effect on papain -like viral protease [30]. So far (status 07/04/2020) the search in clinical \ntrials (humans only) yielded no completed clinical trial, but two ongoing randomised controlled trials \n(RCTs) (NCT04252274, ChiCTR2000029541), both with an estimated completion  date in December 2020. \nDetailed information about the two ongoing RCTs is given in Table 3.4-1. \nDrug used in Covid -19 patients: results of publications  \nUntil now (stat us: 07/04/2020) no scientific publication on clinical trials of darunavir (Prezista\u00ae) in \nCovid -19 patients could be identified.   \n \n \n  Table 3.4-1: Darunavir in clinical trial registry  \nAbbreviations: EMA \u2013 European Medicines Agency, FDA \u2013 Food and Drug Administration, HIV - Human immunodeficiency virus, Pts. - Patients  \n  \n \nAbout the drug under consideration  \nChloroquine is a anti -malarial drug with theraputic as well as prophylactic indication. It has due to its \nanti-inflammatory and immunomodulating effects, further therapeutic indications for rheumatoid \narthritis and lupus. In recent in -vitro s tudies it is indicated, that the drug has also anti -viral effects, e.g. \non the cell -entry mechanism of coronavirus like SARS -CoV -2, which is causing Covid -19 [64]. \nChloroquine is closely related to hydroxychloroquine and shares the same pharmacokinetics, but showing \na lower safety level and more concerns in drug -drug interactions.  \nChloroquine has been approved by the American Food and Drug Administratio n (FDA) since 09/07/1975 \nas suppressive treatment and for acute attacks of malaria due to P. vivax , P. malariae , P. ovale , and \nsusceptible strains of P. falciparum . It is also indicated for the treatment of extraintestinal amebiasis. \nFurther it has an  emergency use authorization for Covid -19. By the European Medicines Agency (EMA) \nit is not approved (but has an orphan designation for the treatment of glioma since 19/11/2014), whereas \nit is national approved in Austria since 19/10/1959 for prevention an d treatment of malaria due to P. vivax , \nP. malariae , P. ovale , and susceptible strains of P. falciparum . It is also indicated for treatment of \n(juvenile) chronic rheumatoid arthritis and systemic lupus.  \nDrug used in Covid -19 patients: ongoing studies  \nRece ntly, chloroquine is also applied in patients with Covid -19 infection. The search in clinical trials \n(humans only) yielded no completed study on the safety and efficacy chloroquine for Covid -19 patients. \nEight ongoing phase IV controlled trials (ChiCTR2000 029988, ChiCTR2000029975, ChiCTR2000029542, \nChiCTR2000029609, ChiCTR2000029741, ChiCTR2000029898, ChiCTR2000029992, \nChiCTR2000029899), one ongoing Chinese controlled trial with phase 0 (ChiCTR2000030054), and  two \nadditional controlled trails with not repo rted phases  (ChiCTR2000029939, ChiCTR2000029935) could \nbe identified.  \nThe eight phase IV controlled trials are expected to be completed in spring/early summer 2020, but no \nresults are availabe yet. The controlled trial in phase 0 is expected to be comple ted in May 2020 and the \ntwo controlled trials with no defined phase are expected to be finished in February 2021. Table 3.5-1. \nDrug used in Covid -19 patients: results o f publications  \nSo far (status: 07/04/2020) one publication [8] [ChiCTR2000029542]) on the effectiveness and safety of \nchloroquine in adults hospitalised with Covid -19 could be identified. In [8] 22 hospitalised Covid -19 \npatients were assigned to chlo roquine (n=10) or comparator treatment lopinavir/ritonavir (n=12). \nComparing the virological cure (RT -PCR negative) of the chloroquine intervention group to the \nlopinavir/ritonavir  comparator group, the percentages of patients who became SARS -CoV -2 negati ve were \nslightly higher at day 7 (70.0% vs. 58.33%, RR= 1.20 [CI: 0.60, 2.40]), day 10 (90.0% vs. 75.0%, RR= 1.20 \n[CI: 0.84, 2.00]), and day 14 (100.0% vs. 91.67%, RR= 1.09 [CI: 1.00, 1.33]). Also the proportion of CT -\nscan improvement of the chloroquine in tervention group compared to the lopinavir/ritonavir  comparator \ngroup, was higher at day 10 (20.0% vs. 8.33%, RR=2.4 (CI: 0.14, 12.32) and day 14 (100.0% vs. 75.0%, \nRR=1.33 [CI: 1.00, 2.00]). In addition, patients treated with chloroquine were discharged from hospital \nmuch earlier than patients treated with lopinavir/ritonavir (clinical recovery at day 10: 80.0% vs. 58.33%, \nRR= 1.37 [CI: 0.80, 2.80]; hospital discarge at day 14: 100.0% vs. 50.0%, RR= 2.0 [CI: 1.33,4.00]). \nConcerning all adverse events that  occured during the follow -up of 14 days, the intervention group showed \n9 different adverse events, the comparator group 10. Neurological events were more common in the \nlopinavir/ ritonavir comparator group. Severe adverse events were not reported. Overall , a slight clinical \nbenefit could be observed with chloroquine treatment beyond lopinavir/ ritona vir treatment in \nhospitalised a dult patients with Covid -19. Detailed information about the study results are presented in  \nTable 3.5 -2. \n  \nTable 3.5-1: Chloroquine in clinical trial registry  \n \nTable 3.5 1 : Chloroquine in clinical trial registry  (Cont inued )\n \n  \nTable 3.5 1: Chloroquine in clinical trial registry  (Cont inued ) \n \n \nTable 3.5-2: Publications  on clinical trials on product Chloroquine  \n \n \n \n \n \n \n \n \n \n \n \nCG \u2013 Comparator group, CI \u2013 Confidence intervall, CT \u2013 Computer Tomography, IG \u2013 Intervention group,  \nN \u2013 Number of adverse events, NR \u2013 Not reported, Pts \u2013 Patients, RR \u2013 Risk ratio  \n \nAbout the drug under consideration  \nHydroxychloroquine is a common anti -malarial drug with theraputic as well as prophylactic indication. \nDue to its anti -inflammatory and immunomodulating effects, it is also used as treatment of rheumatoid \narthritis and lupus. In recent in -vitro studies it is indicated, that the drug has also anti -viral effects, e.g. \non the cell -entry mechanism of coronavirus like SARS -CoV -2, which is causing Covid -19 [65]. \nHydroxychloroquine is closely related to cloroquine and shares the  same pharmacokinetics, but showing \na higher safety level and fewer concerns in drug -drug interactions.  \nHydroxychloroquine (Plaquenil\u00ae) has been approved by the American Food and Drug Administration \n(FDA) since 18/04/1955 as treatment of uncomplicated mal aria due to P. falciparum, P. malariae , P. ovale , \nand P. vivax . It is indicated for the prophylaxis of malaria in geographic areas where chloroquine \nresistance is not reported. Further it has an  emergency use authorization for Covid -19. By the European \nMed icines Agency (EMA) it is not approved (but has an orphan designation for the treatment of \nantiphospholipid syndrome), whereas in Germany it is approved as antimalarial treatment as well as \nindication for the tratment of immune -mediated conditions like rhe umatoid arthritis, discoid and \nsystemic lupus erythematosus.  \nDrug used in Covid -19 patients: ongoing studies  \nRecently, hydroxychloroquine is also applied in patients with Covid -19 infection. The search in clinical \ntrials (humans only) yielded no completed study on the safety and efficacy hydroxychloroquine for Covid -\n19 patients. Eight ongoing phase IV controlled trials (NCT04316377, EudraCT: 2020 -000982 -18, \nChiCTR2000029559, ChiCTR2000029992, ChiCTR2000029898, ChiCTR2000029899, \nChiCTR2000029868, ChiCTR20000 29740), 5 ongoing phase III controlled trials (NCT04315896, \nNCT04321278, NCT04308668, NCT04315948, EudraCT: 2020 -000890 -25), one ongoing phase II \ncontrolled trial (EudraCT: 2020 -001224 -33) and one additional ongoing Chinese controlled trial with \nphase 0 (C hiCTR2000030054) could be identified.  \nSix phase IV controlled trials are expected to be completed in spring/early summer 2020, but no results \nare availabe yet. One phase IV controlled trial will be finished in spring 2021 and ones ending is not \nfurther specified. The first phase III study is e xpected to be completed in April 2020, the next two in late \nsummer/autumn 2020, another one in March 2023 and the last phase III controlled trial ending is not \nfurther specified. The phase II clinical study has no further details on when it will be complet ed. The \nChinese controlled trial in phase 0 is expected to be completed in May 2020. Table 3.6 -1 presents more \ndetails of the identified ongoing studies.   \nDrug used in Covid -19 patients: results of publications  \nSo far (status: 06/04/2020) three publications  ([66] [EudraCT: 2020 -000890 -25]; [67, 68] \n[ChiCTR2000029559]) on the effectiveness and/or safety of hydroxychloroquine in adults hospitalised \nwith Covid -19 could be identified. Unfortunatly, [67] is not published in English and [68] is currently \navailabe just as pre -print but not yet peer -reviewed, thus not inc luded. In [66] 36 hospitalised Covid -19 \npatients (per -protocol) were assigned to hydroxychloroquine (n=20) or standard therapies (n=16) \nincluding symptomatic treatment and antibiotics based on clinical judgment. Comparing the proportion \nof patients that had negative PCR results in nasopharyngeal samples showed a significantly difference \nbetween the intervention group and control group at days 3 -4-5 and 6 post -inclusion (Day 6: 14 (70.0%) \nvs. 2 (12.5%), difference 57.5 percentage points, p=0.001). Some patients of the intervention group where \ntreated with azithromycin (n=6) in addition to the single drug hydroxychloroquine (n=14). The \nproportion of pa tients with negative PCR results in nasopharyngeal samples that where treated with \nhydroxychloroquine in combination with azithromycin compared to the patient treated with \nhydroxychloroquine or the control group was significantly different at days 3 -4-5 an d 6 post -inclusion \n(Day 6: 8 (57.1%) vs. 6 (100%) vs. 2 (12.5%), p=<0.001). Any (severe) adverse events were not reported in \nthis publication, but will be in the next ones. Detailed information about the study results are presented \nin Table 3.6-2. \n. \nTable 3.6-1: Hydroxychloroquine (Plaquenil\u00ae)  in clinical trial registry  \n \nTable 3.6-1: Hydroxychloroquine (Plaquenil\u00ae)  in clinical trial registry  (Cont inued ) \n \n \n \nTable 3.6-1: Hydroxychloroquine (Plaquenil\u00ae)  in clinical trial registry  (Cont inued ) \n \nTable 3.6-1: Hydroxychloroquine (Plaquenil\u00ae)  in clinical trial registry  (Continued ) \n \n \n \n \n  Table 3.6-2: Publications  on clinical trials on product Hydroxycloroquine (Plaquenil \u00ae) \n \n \n \n \n \n \n \n \n \n \n \n \nCG \u2013 Control group, IG \u2013 Intervention group, LRTI \u2013 Lower tract respiratory infection,  \nNR \u2013 Not reported, Pts \u2013 Patients, SD \u2013 Standard deviaton, URTI \u2013 Upper tract respiratory infection  \n \nAbout the drug under consideration  \nCamistat Mesilate (Foipan\u00ae) is classified as a so -called serine protease inhibitor, blocking several \npancreatic and plasmatic enzymes like trypsin, thrombin and plasmin [69]. It is licenced for pancreatitis \nand reflux esophagitis after gastrectomy in Japan (PMDA). Further, studies showed effects on the cell -\nentry mechanism of coronaviruses (e.g. SARS -CoV and SARS -CoV -2) in in -vitro human cells [70, 71] as \nwell as in pathogenic mice -models [72] by inhibiting the enzyme Transmembrane protease, serine 2 \n(TMPRSS2). Camistat Mesilate (Foipan\u00ae) ist not approved for  any anti -viral use (FDA, EMA).  \nDrug used in Covid -19 patients: ongoing studies  \nIn the course of the current urgent search for treatments against the novel Covid -19 disease (caused by \nSARS -CoV -2), Camistat Mesilate (Foipan\u00ae) is being considered as a potential therapeutic agent. \nAlthough, only one randomised clinical trial (NCT04321096 ) is registered. This trial (phase II) on the \nefficacy of Camistat Mesilate (Foipan\u00ae) is still ongoing and recruition of patients is pending. The \npresented study is expected to be completed within a total of 9 months at end of December 2020. More \ninformati on is listed in Table 3.7-1 \nDrug used in Covid -19 patients: results of publications  \nUntil now no scientific publication on clinical trials of Camostat M esilate (Foipan\u00ae) in Covid -19 patients \ncould be identified (status: 03/04/2020).  \nTable 3.7-1 Camostat  Mesilate  (Foipan\u00ae)  in clinical trial registry  \n \n \nDrug under consideration  \nAPN01 is a recombinant human Angiotensin Converting Enzyme 2 (rhACE2) developed by Apeiron \nBiologics under Phase 2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial \nhypertension) [73]. ACE2 was identified as the functional SARS -CoV receptor  in vivo [74]. The receptor \nbinding do main (RBD) of SARS -CoV -2 is similar to the SARS -CoV RBD, indicating a possible common \nhost cell receptor. Recently, ACE2 has been shown to be the cellular entry receptor for the novel \ncoronavirus SARS -CoV -2. The rhACE 2 docks at the spike proteins on the s urface of the Covid -19 virus, \nand thus prevents the virus from attaching to the cells. Treatment with rHACE2 could be used to not only \nobstruct viremia but also protect lungs from injury [75]. \nThe therapy with APN01 is currently not approved by the European Medicine Agency (EMA) and Food \nand Drug Administraion (FDA) for COVID -19. \nOngoing studies  \nThe search in two clinic al trial registers (humans only) yielded no completed study on the safety and \nefficacy of RVD in COVID -19 patients.  One ongoing phase 2 randomised controlled trial (RCT) to assess \nclinical efficacy of rhACE2/APN01 using a composite outcome of all cause -death or need of invasive \nmechanical ventilationas was identfied. The estimated completion date of the trial is in November 2020.  \n \n \n  Table  3.8-1 displays more details of the identified ongoing trials.  \nResults of publications  \nA hand search on the 7th of April 2020 in PubMed was conducted and gave 0 hits. So far no relevant \nfinished publications or finished trials assessing the efficacy and safety could be id entified. First results \ncan be expected on the 10th of November 2020 (NCT04335136).   \n \n \n  Table 3.8-1: \n in clinical trial registry  \nNR = Not reported, rhACE2 = Recombinant Human Angiotensin -converting Enzyme 2  \n \nDrug under consideration  \nTocilizumab ( RoActemra ) is a human monoclonal antibody that specifically binds to soluble and \nmembrane -bound interleukin (IL) -6 receptors (IL -6R\u03b1), and inhibits IL -6-mediated signalling [76]. It is \nlicensed in the EU for treating:  \n\uf0b7 rheumatoid arthritis in adults  \n\uf0b7 giant cell arteritis in adults  \n\uf0b7 active systemic juvenile idiopathic arthritis in patients aged \u22652 years  \n\uf0b7 juvenile  idiopathic polyarthritis in patients aged \u22652 years  \n\uf0b7 chimeric antigen receptor (CAR) T cell -induced severe or life -threatening cytokine release \nsyndrome (CRS) in patients aged \u22652 years [76]. \nWhen used to treat CRS, it is  given as a 60 -minute intravenous (IV) infusion in a dose of 8mg/kg (in \npatients weighing \u226530kg) or 12mg/kg (in patients weighing <30kg), to a maximum of 800mg per infusion \n[76]. Up to three additional doses of RoActemra  may be administered, 8 hourly. When treating other  \nconditions (stated above), RoActemra  can be administered by subcutaneous (SC) injection  or IV infusion \n[76]. \nTocilizumab is being investigated as a possible treatment for patients with moderate to severe or critical \nCOVID -19. \nMost cases of COVID -19 are mild (81%), and patient s\u2019 symptoms are usually self -limiting with recovery \nin two weeks [77]. However, some patients develop severe symptoms and progress rapidly, experiencing \nacute respiratory distress syndrome and septic shock, eventually ending in multiple organ failure [77]. It \nhas been reported that most patients with COVID -19 have increased concentrations of IL -6, C-reactive \nprotein (CRP) and erythrocyte sedimentation rat e [78]. However, severely affected patients appear to have \neven higher plasma levels of pro -inflammatory cytokines and experience severe cytokine storm including \nfeatures of CRS [78, 79]. It has previously been suggested that IL -6 might play a role in the pathogenesis \nof SARS and MERS, other diseases caused by coronaviruses [79]. It is thought that neutralisation of the \ninflammatory pathway induced by IL -6 may reduce mortality.  \nOngoing studies  \nThe search in two clinical trial registers (humans only) yielded no completed study on the safety and \nefficacy of tocilizumab in COVID -19 patients.   \nThere are currently 16 studies on -going or planned.  \nOne multicentre phase IV randomised controlled trial (RCT), to test the safety and effectiveness of \nindivi dually or simultaneously blocking IL -6 and IL -1 versus standard of care on blood oxygenation and \nsystemic CRS in patients with COVID -19 coronavirus infection and acute hypoxic respiratory failure and \nsystemic CRS, is due to start recruiting in Belgium in A pril 2020 ( NCT04330638 ; COV -AID). It will have \nfive active treatment arms, including monotherapy with IV tocilizumab, SC anakinra (an IL -1 inhibitor) \nand SC siltuximab (an IL -6 inhibitor),  and combination therapy with tocilizumab plus either anakinra or \nsiltuximab. The estimated completion date is December 2020.  \nA double -blind phase III RCT ( NCT04320615 ; COVACTA; 2020 -001154 -22) to evaluate the efficacy, \nsafety, pharmacodynamics, and pharmacokinetics of IV tocilizumab versus placebo in combination with \nstandard of care (SOC) in 330 adult s hospitalised with severe COVID -19 pneumonia was due to start on \nthe 3rd of April. It has an estimated completion date of September 2021.  \nThere are nine phase II trials assessing the efficacy of one or two doses of IV or SC tocilizumab.  \n\uf0b7 A double -blind p lacebo -controlled RCT ( NCT04335071 ; CORON -ACT), due to start in \nSwitzerland in April 2020, has a completion date of October 2020.  \n\uf0b7 The open -label COPERNICO RCT ( NCT04335305 ) will evaluate the efficacy of tocilizumab \ncombined with pembrolizumab compared to standard care in 24 adults with COVID -19 \npneumonia and bad prognostic factors who are nonresponsive to frontline therapy  within 48 \nhours from treatment initiation. It has yet to start recruiting, and has an estimated completion \ndate of May 15, 2020.  \n\uf0b7 Another open -label RCT ( NCT04333914 ; IMMUNONCOVID) will compare the efficacy of a \nsingle IV infusion of tocilizumab with a chloroquine analog (GNS561), an anti PD -1 (nivolumab) \nversus standard of care in patients with advanced or metastatic cancer who have Sars -CoV -2 \ninfection not eligible to a resuscitation un it. It is due to start in April 2020 in France, and \ncomplete in August 2020.  \n\uf0b7 An RCT ( NCT04331808 ; CORIMUNO -TOC) is recruiting patients with moderate or severe \npneumonia associated with COV ID-19 requiring no mechanical ventilation or critical \npneumonia requiring mechanical ventilation. The estimated completion date is December 2021.  \n\uf0b7 TOCIVID is an open -label RCT due to start on the 4th of April with an estimated completion date \nin June 2021 ( NCT04322773 ). This study will compare the effect of single doses of either one of \nthree IL -6 inhibitors (SC tocilizumab, IV tocilizumab and SC sarilumab) with standard of care,  \non time to independence from supplementary oxygen therapy, measured in days from baseline \nto day 28, in patients with severe SARS -CoV -2 pneumonia.  \n\uf0b7 An open -label RCT, TOCOVID ( NCT04332094 ), and are re cruiting in Spain and Italy, \nrespectively. The first is a randomised trial and will assess use of tocilizumab in combination \nwith hydroxychloroquine and azithromycin; it is due to complete October 2020.  \n\uf0b7 Three single -arm studies are planned. The first, TOC IVID -19, is recruiting in Italy \n(NCT04317092 ; 2020 -001110 -38), with an estimated completion date of  19th December 2022.  \nCOVIDOSE is recruiting in the US ( NCT04331795 ) and recruiting 50 hospitalised, non -critically \nill patients with COVID -19 pneumonitis with clinical risk factors for clinical decompensation, \nintensive care utilisation, and death. It is due to start April 2020, and finish in December 2020. \nThe third study ( NCT04315480 ) has finished recruiting and is due  to complete in May 2020.  \nIn addition, there are three further trials for which the phase is not stated. TOSCA ( NCT04332913 ) is a \nprospective open -label study assessing tocilizumab efficac y and safety in 30 adults with COVID -19 \ncomplicated by acute distress respiratory syndrome and CRS. A three -arm active -comparator RCT will \ncompare tocilizumab plus favipiravir, favipiravir monotherapy and tocilizumab monotherapy in China \n(NCT04310228 ). The TACOS trial, a r etrospective observational cohort trial,  is recruiting in China and \ncomparing the efficacy and safety of tocilizumab and continuous renal replacement therapy in \nmanagement  of CRS triggered by COVID -19 (NCT04306705 ). Their estimated completion dates are \nMarch 2021, May 2020 and June 2020, respectively.  \nTable 3.9-1 displays more details of these 14 identified on -going trials.  \nA further two studies were identified but they are not included in Table 3.9-1: \n1. ChiCTR2000029765  \u2013 A multicenter, randomized controlled trial for the efficacy and safety of \ntocilizumab in the treatment o f new coronavirus pneumonia (COVID -19) \n2. 2020 -001386 -37 \u2013 Uno studio randomizzato multicentrico in aperto per valutare l\u2019efficacia della \nsomministrazione precoce del Tocilizumab (TCZ) in pazienti affetti da polmonite da COVID -\n19. \nResults of publications  \nA search on the 7th of April 2020 in PubMed was conducted and gave 11 hits. So far no relevant finished \npublications or finished trials assessing the efficacy and safety could be identified, except for one \nretrospective report describing the experience of using tocilizumab i n severe or critical COVID -19 \npatients [80] (found through searching the reference list in paper 4) .  \nRetrospective analysis of data from 20 patients who received one of two doses of IV tocilizumab 400mg \nshowed 15  (75%) had lowered their oxygen intake and one patient need no oxygen therapy. CT scans \nshowed lung lesion opacity absorbed in 19 patients (90.5%). The percentage of lymphocytes in peripheral \nblood, which decreased in 85.0% patients (17/20) before treatment (mean, 15.52 \u00b1 8.89%), returned to \nnormal in 52.6% patients (10/19) on the fifth day after treatment. Abnormally elevated CRP decreased \nsignificantly in 84.2% patients (16/19). No obvious adv erse reactions were observed.  \n  \n \n \n  Table 3.9-1: Tocilizumab in clinical trial registry  \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \no \no \n\uf0b7 \no \n\uf0b7 \n \n\uf0b7 \no \n \n \n \n \nCRS = cytokine release syndrome; DMARD = disease modifying anti -rheumatic drug; IL = interleukin; IV = intravenous; MTX = methotrexate; RCT = randomised \ncontrolled trial; RA = rheumatoid arthritis; SC = subcutaneous; SOC = standard of care; TNF = tumour necrosis factor   \n \n \n  Table 3.9-2: Tocilizumab in clinical trial registry  (Continued ) \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n \n \n \n \n \n \n \n \nCRS = cytokine release syndrome; DMARD = disease modifying anti -rheumatic drug; IL = interleukin; IV = intravenous; MTX = methotrexate; RCT = randomised \ncontrolled trial; RA = rheumatoid arthritis; SC = subcutaneous; SOC = standard of care; TNF = tumour necrosis factor  \nTable 3.9-3: Tocilizumab in clinical trial registry  (Continued ) \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n \n \nCRS = cytokine release syndrome; DMARD = disease modifying anti -rheumatic drug; IL = interleukin; IV = intravenous;  MTX = methotrexate; RCT = randomised \ncontrolled trial; RA = rheumatoid arthritis; SC = subcutaneous; SOC = standard of car e; TNF = tumour necrosis factor   \n \n \n  \n \nDrug under consideration  \nSarilumab ( Kevzara ) is a human monoclonal antibody that specifically binds to soluble and membrane -\nbound interleukin (IL) -6 receptors (IL -6R\u03b1), and inhibits IL -6-mediated signalling [81]. It is licensed in \nthe EU for treating adults with rheumatoid arthritis, given by subcutaneous (SC) injection [81]. It is being \ninvestigated as a possible tr eatment for patients with moderate to severe or critical COVID -19. \nMost cases of COVID -19 are mild (81%), and patients\u2019 symptoms are usually self -limiting with recovery \nin two weeks [77]. However, some patients develop severe symptoms and progress rapidly, experiencing \nacute respiratory distress syndrome and septic shock, eventually ending in multiple organ failure [77]. It \nhas been reported that most patients with COVID -19 have increased concentrations of IL -6, C-reactive \nprotein (CRP) and erythrocyte sedimentation rate [78]. However, severely affected patients appear to have \neven higher plasma levels of pro -inflammatory cytokines and experience severe cytokine storm includi ng \nfeatures of cytokine release syndrome (CRS) [78, 79]. It has previously been suggested that IL -6 might \nplay a role in the pathogenesis of SARS and MERS, other diseases caused by coronaviruses [79]. It is \nthought that neutralisation of the inflammatory pathway induced  by IL -6 may reduce mortality.  \nExperience of using tocilizumab, another IL -6 inhibitor, in severe or critical COVID -19 patients has been \nreported [80]. Retrospective analysis of data from 20 patients who received one of two doses of intravenous \n(IV) tocilizumab 400mg showed 15  (75%) had lowered their oxygen intake and one patient need no oxygen \ntherapy. CT scans showed lung lesion opacity absorbed in 19 patients (90.5%). The percentage of \nlymphocytes in peripheral blood, which decreased in 85.0% patients (17/20) before treatment (mean, 15.52 \n\u00b1 8.89%), returned to normal in 52.6% patients (10/19) on the fifth day after treatment. Abnormally \nelevated CRP de creased significantly in 84.2% patients (16/19). No obvious adverse reactions were \nobserved.  \nOngoing studies  \nThe search in two clinical trial registers (humans only) yielded no completed study on the safety and \nefficacy of sarilumab in COVID -19 patients.   \nThree on -going phase II / III randomised controlled trials (RCT) to evaluate intravenous (IV) sarilumab \nin patients with COVID -19 have been recruiting patients since March 2020 \u2013 two trials in France \n(NCT04324073 ; CORIMUNO -SARI and NCT04327388 ; 2020 -001162 -12) and one in the US \n(NCT04315298 ). The estimated completion dates are December 2021, June 2021 and April 2021, \nrespectively.  \nAn open -label phase II RCT was due to start on the 4th of April with an estimated completion date of June \n2021 ( NCT04322773 ; TOCIVID) . This study will compare the effect of single doses of one of three IL -6 \ninhibitors (SC sarilumab, SC tocili zumab and IV tocilizumab) with standard of care, on time to \nindependence from supplementary oxygen therapy, measured in days from baseline to day 28, in patients \nwith severe SARS -CoV -2 pneumonia. A further open -label phase II non -randomised controlled stud y is \nplanned to evaluate the safety and effectiveness of potential anti -COVID -19 treatments, as an adjunct to \nclinical standard of care treatment, in hospitalised persons with moderate to severe COVID -19 disease \n(NCT04321993 ). Recruitment of 1,000 adults is due to start in April 2020, presumably in Canada as the \ntrial is sponsored by Nova Scotia Health Authority (although not stated). Patients will be given either SC \nsarilumab, oral lopinav ir + ritonavir ( Kaletra ), oral hydroxychloroquine sulphate, oral baricitinib \n(Olumiant ) or clinical standard of care. The estimated completion date is July 2021.  \nTable 3.10-1 displays more details of the identified on -going trials.  \nResults of publications  \nA search on the 7th of April 2020 in PubMed was conducted and gave 1 hit. So far no relevant finished \ntrials assessing the efficacy and safety of sarilumab could be ide ntified.   \n \n \n  Table 3.10-1: Sarilumab in clinical trial registry  \n \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n\uf0b7 \n \n \n \n \n \n \n  \n \n \n  \n \n  \nAbout the drug under consideration  \nInterferon beta -1a (INFb) is a cytokine in the inte rferon family used to treat relapsing multiple sclerosis \n(MS). Interferon beta balances the expression of pro - and anti -inflammatory agents in the brain, leading \nto a reduction of neuron inflammation [82]. Clinical observations in mammals infected with the Middle \nEast respiratory syndrome coronavirus (MERS -CoV) have shown clinical improvements with the use of \nINFb; and human trials are also underway to evaluate the effect of lopinavir/ritonavir in combination \nwith INFb in patients with MERS -CoV. Finding of these studies have led to explorat ion of treatment with \nINFb in COVID -19 [83]. \nTwo pharmaceuticals which the active substance INFb are commercially available: Rebif\u00ae and Avonex\u00ae. \nThey are used to slow the progression of disability and reduce the number of relapses in MS. Rebif is \napproved by the European Medicines Agency (EMA) since 1998 and by the American Food and Drug \nAdministration (FDA) since 2002. Avonex is approved by EMA since 1997 and by the FDA since 1996. \nBoth drugs are approved for the treatment of relapsing forms of mu ltiple sclerosis (MS), in cases of \nclinically isolated syndromes, as well as relapsing remitting disease, and active secondary progressive \ndisease in adults.  \nDrug used in Covid -19 patients: ongoing studies  \nThe search in clinical trials (humans only) yielde d no completed studies on the safety and effectiveness of \nInterferon beta -1a for Covid -19 patients. Four ongoing trials could be identified: one phase II randomised \ncontrolled trial (RCT) (EudraCT 2020 -001023 -14), one phase III randomised trial (NCT0431594 8), one \nphase IV randomised, embedded, multifactorial adaptive platform trial (NCT02735707) and one \nobservational study with unknown study phase (NCT04314817). The phase IV trial started in 2016 with \nthe indications community -acquired pneumonia and influen za; and added COVID -19 just recently. The \nother three trials all started in March 2020. Results are expected in May 2021, January 2022 and \nJanuary/March 2023. Three of the studies assess multiple interventions at the same time, including \ninterferon beta -1a. One of the studies assesses interferon beta -1a in combination with \nLopinavir/Ritonavir. Table 3.11-1 presents more details of the identified ongoing studies.  \nDrug used in Covid -19 patients: results of publications  \nCurrently there are no completed studies. First results are expected in May 202 1.    \n \n \n  Table 3.11-1: Interferon beta -1a in clinical trial registry\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n  \n[1] Pang J., Wang M. X., Ang I. Y. H., Tan S. H. X., Lewis R. F., Chen J. I., et al. Potential Rapid \nDiagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019 -nCoV): A Systematic \nReview. J Clin Med. 2020;9(3). Epub 2020/03/01.  \n[2] European Medicines Agency (EMA). Global regulators stress need for robust evidence on COVID -19 \ntreatments. 2020; Available from: https:// www.ema.europa.eu/en/news/global -regulators -stress -\nneed -robust -evidence -covid -19-treatments . \n[3] European Medicines Agency (EMA). EMA establishes task force to take quick and coordinated \nregulatory action related to COVID -19 medicines. 2020; Available from: \nhttps:// www.ema.europa.eu/en/documents/press -release/ema -establishes -task-force -take-quick -\ncoordinated -regulatory -action -related -covid -19-medicines_en.pdf . \n[4] Verband der forschenden Pharmaunternehmen (VfA). Impfstoffe zum Schutz vor Covid -19, der neuen \nCoronavirus -Infektion; Therapeutische Medikamente gegen die Coronavirusinfektion Covi d-19. 2020; \nAvailable from: https:// www.vfa.de/de/arzneimittel -forschung/woran -wir-forschen/impfstoffe -\nzum-schutz -vor-coronaviru s-2019 -ncov;  https:// www.vfa.de/de/arzneimittel -forschung/woran -wir-\nforschen/therapeutische -medikamente -gegen -die-coronavirusinfektion -covid -19. \n[5] Cao B, Wang Y, Wen D, Liu D, Wang J, Fan G, et al. A Trial of Lopinavir \u2013Ritonavir in Adults \nHospitalized with Severe Covid -19. NEJM. 2020:13.  \n[6] Canadian Pharmacists Association. Treatment of COVID -19 with chloroquine or hyd roxychloroquine. \nOttawa: CPhA; 2020 [cited 09.04.2020]; Available from: https:// www.pharmacists.ca/cpha -\nca/assets/File/cpha -on-the-issues/CQ -HCQ -COVI D-FINAL -EN.pdf . \n[7] Centre for Evidence -Based Medicine (CEBM). Chloroquine and hydroxychloroquine: Current \nevidence for their effectiveness in treating COVID -19. 2020; Available from: \nhttps:// www.cebm.net/covid -19/chloroquine -and-hydroxychloroquine -current -evidence -for-their -\neffectiveness -in-treating -covid -19/. \n[8] Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID -19 with Chloroquine. Journal of \nMolecular Cell Biology. 2020(mjaa014).  \n[9] World Health Organisation (WHO). DRAFT landscape of COVID -19candidate vaccines \u2013 21 March \n2020. 2020 [cited 2020 03.04.]; Available from: https:// www.who.int/blueprint/priority -diseases/key -\naction/novel -coronavirus -landscape -ncov -21march2020.PDF?ua=1 . \n[10] Labor Journal. Alle gegen einen. Das Coronavir us h\u00e4lt Biotech -Firmen weltweit auf Trab. Die einen \nentwickeln Apps, die anderen Impfstoffe. 2020; Available from: \nhttps:// www.laborjournal.de/editorials/1964.php . \n[11] Clinical Trials Arena. First US clinical trial of Covid -19 vaccine candidate begins. 2020; Available \nfrom: https:// www.clinicaltrialsarena.com/news/first -us-covid -19-vaccine -trial-moderna/ . \n[12] Precision vaccination. Ad5 -nCoV COVID -19 Vaccine. 2020a; Available from: \nhttps:// www.precisionvaccinations.com/vaccines/ad5 -ncov -covid -19-vaccine . \n[13] University of Oxfor d. Oxford team to begin novel coronavirus vaccine research. 2020 [03.04.2020]; \nAvailable from: http://www.ox.ac.uk/news/2020 -02-07-oxford -team -begin -novel-coronavirus -\nvaccine -research . \n[14] Inovio Pharmaceuticals. Inovio Accelerates Timeline for COVID -19 DNA Vaccine INO -4800. 2020 \n[02.04.2020]; Available from: http://ir.inovio.com/news -and-media/news/press -release -\ndetails/2020/Inovio -Accelerates -Timeline -for-COVID -19-DNA -Vaccine -INO -4800/default.aspx . \n[15] Inovio Pharmaceuticals. Inovio Collaborating With Bei jing Advaccine To Advance INO -4800 Vaccine \nAgainst New Coronavirus In China. 2020 [03.04.2020]; Available from: http://ir.inovio.com/news -\nand-media/news/press -release -details/2020/Inovio -Collaborating -With -Beijing -Advaccine -To-\nAdvance -INO -4800 -Vaccine -Against -New -Coronavirus -In-China/default.aspx . \n[16] Precision vaccination. SARS -CoV -2 Vaccine Candidate Ready For Clinical Study. Inovio \nPharmaceuticals INO -4800 vaccine candidate prepares for human studies. 2020b; Available from: \nhttps:// www.precisionvaccinations.com/inovio -pharmaceuticals -ino-4800 -vaccine -candidate -\nprepares -human -studies    \n[17] Nature biotechnology. The pandemic pipeline. 2020; Available from: \nhttps:// www.nature.com/articles/d41587 -020-00005 -z. \n[18] Bundesministerium f\u00fcr Bildung und Forschung (BMBF). CureVac und CEPI bauen Kooperation zur \nEntwicklung eines Impfstoffs gegen das Coronavirus nCoV -2019 aus. 2020; Available fro m: \nhttps:// www.bmbf.de/de/curevac -und-cepi-bauen -kooperation -zur-entwicklung -eines -impfstoffs -\ngegen -das-coronavirus -10797.html . \n[19] European Commission. Coronavirus: Commission offers financing to innovative vaccines company \nCureVac. 2020 [cited 2020 03.04.]; Available from: \nhttps://ec.europa.eu/commission/presscorner/detail/en/IP_20_474  \n[20] European Commission. New research pr ojects on Coronavirus. Outcome of emergency funding action \nfor coronavirus SARS -CoV -2 outbreak: 17 new projects. 2020b; Available from: \nhttps://ec.europa.eu/info/sites/info/files/research_and_innovation/research_by_area/documents/ec_rt\nd_cv -projects.pdf?fbc lid=IwAR27kaCBJYfkkpaEZFHJsisUifPq3O6nT1ukFvk8knHkN6qVGuxvlu -\nQ0eE.  \n[21] BioNTech. BioNTech reports rapid progress on COVID -19 vaccine program to address global public \nhealth threat. 2020; Available from: https://investors.biontech.de/news -releases/news -release -\ndetails/biontech -reports -rapid -progress -covid -19-vaccine -program -address.  \n[22] Themis Bioscience. CEPI collaborates with the Institut Pasteur in a consortium to develop COVID -19 \nvaccine 2020; Available from: https:// www.themisbio.com/cepi -collaborates -with -the-institut -\npasteur -in-a-consortium -to-develop -covid -19-vaccine/   \n[23] Coalition for Epidemic Preparedness Innovations (CEPI). New vac cines for a safer world. Learn more \nabout COVID -19. 2020; Available from: https://cepi.net/  \n[24] Karolinska Institutet. Vaccine development against coronavirus enters next phase. 2020b; Available \nfrom: https://news.ki.se/vaccine -development -against -coronavirus -enters -next-phase  \n[25] Karolinska Institutet. Three KI -led coronavirus projects selected in EU funding round. 2020a; \nAvailable from: https://news.ki.se/three -ki-led-coronavirus -projects -selected -in-eu-funding -round.  \n[26] adapt VAC. Adaptvac\u2019s ground -breaking technology central to new \u20ac2.7m EU grant funded covid -19 \nvaccine effort. 2020; Available from: https:// www.adaptvac.com/news . \n[27] Jackson LA. Safety and Immunogenicity Study of 2019 -nCoV Vaccine (mRNA -1273) for Prophylaxis \nSARS CoV -2 Infection. 2020 [cited 2020 07.04.]; Available from: \nhttps://clinicaltrials.gov/ct2/show/NCT04283461.Jackson.  \n[28] Hodgson J. The pandemic pipeline. 2020 [cited 2020 03.04.]; Available from: \nhttps:// www.nature.com/articles/d41587 -020-00005 -z. \n[29] National Institute of Health (NIH). NIH clinical trial of investigational vaccine for COVID -19 begins. \n2020 [cited 2020 07.04.]; Available from: htt ps:// www.nih.gov/news -events/news -releases/nih -\nclinical -trial-investigational -vaccine -covid -19-begins . \n[30] Denis M, Vanderweerd V, Verbeke R , Van der Vliet D. Overview of information available to support \nthe development of medical countermeasures and interventions against COVID -19. Living document. \n2020 [03.03.2020]; Available from: https://rega.kuleuven.be/if/pdf_corona.  \n[31] CanSino Biologics Inc . CanSinoBIO\u2019s Investigational Vaccine Against COVID -19 Approved for Phase \n1 Clinical Trial in China.  [02.03.2020]; Available from: \nhttp://www.cansinotech.com/homes/article/show/56/ 153.html . \n[32] BioWorld. China approves first homegrown COVID -19 vaccine to enter clinical trials.  [02.03.2020]; \nAvailable from: https:// www.bioworld.com/articles/433791 -china -approves -first-homegrown -\ncovid -19-vaccine -to-enter -clinical -trials . \n[33] World Health Organisation (WHO). DRAFT landscape of COVID -19candidate vaccines \u201320 March \n2020. 2020 [31.03.2020]; Available from: https:// www.who.int/blueprint/priority -diseases/key -\naction/novel -coronavirus -landscape -ncov -21march2020.PDF?ua=1 . \n[34] 3U.S. National Library of M edicine. A Phase I Clinical Trial in 18 -60 Adults (APICTH). 2020; \nAvailable from: https://clinicaltrials.gov/ct2/show/NCT04313127.  \n[35] Pang J, Wang MX, Ang IYH, Tan SHX, Lewis RF, Chen JI, et al. Potential Rapid Diagnostics, Vaccine \nand Therapeutics for 2019 N ovel Coronavirus (2019 -nCoV): A Systematic Review. Journal of clinical \nmedicine. 2020;9(3). Epub 2020/03/01.   \n[36] Novavax. Novavax Awarded Funding from CEPI for COVID -19 Vaccine Development. 2020 [cited \n2020 06.04.]; Available from: https://ir.novavax.com/news -releases/news -release -details/novavax -\nawarded -funding -cepi-covid -19-vaccine -development.  \n[37] Nature. A surprising player in the race for a SARS -CoV -2 vaccine. 2020 [cited 2020 06.04.]; Available \nfrom: https:// www.nature.com/articles/d42473 -020-00032 -z. \n[38] Drug Development and Delivery. Novavax Advances Development of Novel COVID -19 Vaccine. 2020 \n[cited 2020 06.04.]; Available from: https://drug -dev.com/novavax -advances -development -of-novel -\ncovid -19-vaccine/.  \n[39] Novavax. MATRIX -M\u2122 ADJUVANT TECHNOLOGY. 2020 [cited 2020 06.04.]; Available from: \nhttps://novavax.com/page/10/matrix -m-adjuvant -technology.html.  \n[40] Coalition for Epidemic Preparedness Innovations (CEPI). CEPI partners with University of \nQueensland to create rapid -response vaccines.  [07.04.2020]; Available from: \nhttps://cepi.net/news_cepi/cepi -partners -with -university -of-queensland -to-create -rapid -response -\nvaccines/.  \n[41] The University of Queensland. Race to develop coronavirus vaccine. 2020 [6.04.2020] ; Available from: \nhttps:// www.uq.edu.au/news/article/2020/01/race -develop -coronavirus -vaccine . \n[42] Stackpool I. Australian scientists claim they've ALREADY developed a v accine for coronavirus - but \nthey can't roll it out to people just yet. 2020 [06.04.2020]; Available from: \nhttps:// www.dailym ail.co.uk/news/article -8110909/Australian -scientists -say-vaccine -deadly -\ncoronavirus -roll-yet.html . \n[43] Hennessy J. Australia\u2019s been asked to make a coronavirus vaccine at \u2018unprecedented speed\u2019 business \ninsider. 2020 [06.04.2020]; Available from: https:// www.sciencealert.com/australian -scientists -\nasked -to-make -coronavirus -vaccine -at-unprecedented -speed . \n[44] CureVac AG. What We Do - The Unlimited  Possibilities of mRNA. T\u00fcbingen, Germany: CureVac AG;  \n[cited 2020 03.04.]; Available from: https:// www.curevac.com/mrna -platform . \n[45] CureVac AG. CureVac and CEPI extend their Cooperation to Develop a Vacc ine against Coronavirus \nnCoV -2019 T\u00fcbingen, Germany: CureVac AG; 2020 [cited 2020 03.04.]; Available from: \nhttps:// www. curevac.com/news/curevac -and-cepi-extend -their -cooperation -to-develop -a-vaccine -\nagainst -coronavirus -ncov -2019 . \n[46] CureVac AG. CureVac Announces Positive Results in Low Dose \u2013 1 \u00b5g \u2013 Rabies Vaccine Clinical \nPhase 1 Study T\u00fcbingen, Germany: CureVac AG; 2020 [ci ted 2020 03.04.]; Available from: \nhttps:// www.curevac.com/news/curevac -announces -positive -results -in-low-dose -1-\u00b5g-rabies -\nvaccine -clinical -phase -1-study   \n[47] CureVac AG. COVID -19: Conference Call on Current Developments. T\u00fcbingen, Germany: CureVac \nAG; 2020 [cited 2020 03.04.]; Available from: https:// www.curevac.com/news/conference -call-on-\ncurrent -developments . \n[48] CureVac AG. CureVac CEO Daniel Menichella Discusses Coronavirus Vaccine Development with U.S. \nPresident Donald Trump and Members of Coronavirus Task Force T\u00fcbingen, Germany: CureVac AG; \n2020  [cited 2020 03.04.]; Available from: https:// www.cu revac.com/news/curevac -ceo-daniel -\nmenichella -ber\u00e4t -mit-us-pr\u00e4sident -donald -trump -und-mitgliedern -der-corona -task-force -\nentwicklungsm\u00f6glichkeiten -eines -coronavirus -impfstoffes   \n[49] CureVac AG. Our pipeline: mRNA -based Prophylactic Vaccines. T\u00fcbingen, Germany: C ureVac AG;  \n[cited 2020 03.04.]; Available from: https:// www.curevac.com/our -pipeline . \n[50] U.S. National Library of Medicine. A Study of a Candidate COVID -19 Vaccine (COV001). 2020; \nAvailable from: https://clinicaltrials.gov/ct2/show/NCT04324606.  \n[51] FierceBiotech. Pfizer, BioNTech strike COVID -19 deal, commit multiple R&D sites to vaccine \ndevelopment. 2020 [cited 2020 07.04.]; Available from: \nhttps:// www.fiercebiotech.com/biotech/pfizer -biontech -strike -covid -19-deal-commit -multiple -r-\nd-sites -to-vaccine -development . \n[52] Keown A. Pfizer and BioNTech to Develop mRNA Vaccine for COVID -19. BioSpace; 2020; Available \nfrom: https:// www.biospace.com/article/pfizer -and-biontec h-to-develop -mrna -vaccine -for-covid -\n19/.  \n[53] Pfizer. Pfizer and Biontech to co -develop potential Covid -19 vaccine. 2020; Available from: \npfizer.com/news/press -release/press -release -\ndetail/pfizer_and_biontech_to_co_develop_potential_covid_19_vaccine.  \n[54] Zhang C, H uang S, Zheng F, Dai Y. Controversial treatments: an updated understanding of the \nCoronavirus Disease 2019. Journal of Medical Virology. 2020;n/a(n/a).  \n[55] Kupferschmidt K, Cohen J. Race to find COVID -19 treatments accelerates. Science. \n2020;367(6485):1412 -3. \n[56] 5Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel \nCoronavirus in the United States. New England Journal of Medicine. 2020;382(10):929 -36. \n[57] European Medicines Agency (EMA). EMA provides recommendations on compas sionate use of \nremdesivir for COVID -19. 2020 [cited 2020 03.04.2020]; Available from: \nhttps:// www.ema.europa.eu/en/news/ema -provides -recomme ndations -compassionate -use-\nremdesivir -covid -19. \n[58] Food and Drug Administration (FDA). Coronavirus (COVID -19) Update: FDA Continues to \nFacilitate Development of Treatments. 2020 [cited 2020 03.04.2020]; Available from: \nhttps:// www.fda.gov/news -events/press -announcements/coronavirus -covid -19-update -fda-\ncontinues -facilitate -development -treatments . \n[59] Fundacion Epistemonikos.  Systematic review - preliminary report Lopinavir/ritonavir for the \ntreatment of COVID -19. 2020 [06/04/2020]; Available from: \nhttps:// www.epistemonikos.cl/2020/03/20/systematic -review -preliminary -report -lopinavir -\nritonavir -for-the-treatment -of-covid -19/. \n[60] Should favipiravir be used for COVID -19? Ministry of Health Singapore and Agency for Care \nEffectiveness2020 [06/04 /2020]; Available from: \nhttps:// www.moh.gov.sg/docs/librariesprovider5/clinical -evidence -summaries/favipiravir -for-\ncovid -19-(26-march -2020).pdf . \n[61] Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID -19). Drug \nDiscoveries & Therapeutics. 2020;14(1):58 -60. \n[62] Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus Arbidol for COVID -19: A \nRandomized Clinical Trial. 2020.  \n[63] McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in \nadults. Drugs 2009;69(4):477 -503. \n[64] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit \nthe recently emerged novel coronavirus (2019 -nCoV) in vitro. 2020(1748 -7838 (Electronic)).  \n[65] Yao X, Ye F, Zhang M, Cui C, Huang B, Nu P, et al. In Vitro Antiviral Activity and Projection of \nOptimized Dosing Desi gn of Hydroxychloroquine for the T reatment of Severe Acute Respiratory \nSyndrome Coronavirus 2 (SARS -CoV -2). Clin Infect Dis. 2020;ciaa237.  \n[66] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and \nazithromycin as a treatm ent of COVID -19: results of an open -label non -randomized clinical trial. Int J \nAntimicrob Agents. 2020:105949. Epub 2020/03/25.  \n[67] Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine in treatment of \npatients with common corona virus disease -19 (COVID -19). J Zhejiang Univ (Med Sci). 2020;49(1):0 -. \n[68] Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with \nCOVID -19: results of a randomized clinical trial. medRxiv. 2020;pre -print, not revie wed.  \n[69] Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and \ntrypsin. Biochim Biophys Acta. 1981;661(2):342 -5. Epub 1981/10/13.  \n[70] Hoffmann M, Kleine -Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS -CoV -2 Cell \nEntry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. \nCell. 2020;181. Epub 2020/03/07.  \n[71] Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human \nbronchial epithelial cells  with serine and cysteine protease inhibitors prevents severe acute respiratory \nsyndrome coronavirus entry. J Virol. 2012;86(12):6537 -45. Epub 2012/04/13.  \n[72] Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R, Jr., Nunneley JW, et al. Protease inhibitors \ntargeti ng coronavirus and filovirus entry. Antiviral Res. 2015;116:76 -84. Epub 2015/02/11.   \n[73] Apeiron Biologics. APN01. 2020 [cited 2020 07.04.2020]; Available from: https:// www.apeiron -\nbiologics.com/project -overview/#APN01 . \n[74] Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 \n(ACE2) in SARS coronavirus -induced lung injury. Nature medicine. 2005;11(8):875 -9. Epub \n2005/07/10.  \n[75] Monteil V, Hyesoo  Kwon, Patricia Prado, Astrid Hagelkr\u00fcys, Reiner A. Wimmer, Martin Stahl, et al. \nInhibition of SARS -CoV -2 infections in engineered human tissues using clinical -grade soluble human \nACE2. 2020 [cited 2020 07.04.2020]; Available from: https:// www.cell.com/pb -\nassets/products/coronavirus/CELL_CELL -D-20-00739.pdf . \n[76] European Medicines Agency. RoActemra (tocilizumab). Amsterdam: EMA; 2020 [cited 17.10.2019]; \nAvailable from: h ttps:// www.ema.europa.eu/en/medicines/human/EPAR/roactemra . \n[77] Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated intrim review and lessons from \nSARS -CoV and MERS -CoV. Int  J Infect Dis [Internet]. 2020 Apr 1 PMC7118633]. Available from: \nhttps://doi.org/10.1016/j.ijid.2020.03.071.  \n[78] Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID -19): a clinical update. Frontiers of \nMedicine. 2020.  \n[79] Lu C -C, Chen M -Y, Chang Y -L. Potential therapeutic agents against COVID -19: What we know so far. \nJournal of the Chinese Medical Association. 2020;Latest Articles.  \n[80] Xu X, Han M, Li T, Sun W, Dongsheng W, Fu B, et al. Effective Treatment of Severe COVID -19 \nPatients with Tocilizumab2020. Available from: \nwww.chinaxiv.org/user/download.htm?id=30387&filetype=pdf . \n[81] European Medicines Agency (EMA). EPAR summary for the public: Kevzara (sa rilumab). 2017; \nAvailable from: https:// www.ema.europa.eu/en/medicines/human/EPAR/kevzara . \n[82] Murdoch D, Lyseng -Williamson KA. Spotlight on subcutaneous recombinant interferon -beta-1a \n(Rebif) in relapsing -remitting multiple sclerosis. BioDrugs. 2005;19(5):323 \u20135. \n[83] Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS). COVID -19 et interf\u00e9rons. \nQu\u00e9bec, Qc: Gouvernement du Qu\u00e9bec; 2020 [cited 09.04.2020]; 6]. Available from: \nhttps:// www.inesss.qc.ca/fileadmin/doc/INESSS/COVID -19/COVID -19_interferons.pdf . \n \n  \n  \n \n \n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}